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 CHAPTER I: INTRODUCTION 
 
Sarcopenia 
 As an individual increases in age, a decrease in muscle mass and strength occurs 
(Rogers & Evans, 1993).  This normal age-related decrease in muscle mass with 
advancing age is termed sarcopenia (Roubenoff, 2000), and occurs in both men and 
women (Hughes et al., 2001).  The decrease in muscle mass associated with aging occurs 
more rapidly in the physically inactive than their active counterparts.  In physically 
inactive people, there is a loss of approximately 3-5% of muscle mass each decade after 
the age of 30, and a parallel decline in muscle strength [reviewed by (Nair, 1995)].  There 
is a greater loss in fast twitch muscle fibers than in slow-twitch muscle fibers.  
Additionally, a decrease in muscle cell size, particularly in type II muscle fibers (or fast 
twitch fibers), is seen in the elderly (Rogers & Evans, 1993).  In addition to this decrease 
in muscle mass and strength, lean body mass slowly decreases throughout adulthood.  
Lean body mass is highest in the third decade, after which it falls slowly for the next two 
decades, and then more rapidly.  Body fat content also progressively rises (Forbes & 
Reina, 1970).  Sarcopenia decreases the ability of the elderly population to perform 
activities of daily living.  This decrease in muscle mass and strength are linked to an 
increased risk of falls and fractures in this population (Deschenes, 2004).  This causes 
decreased independence and quality of life in the elderly.  Sarcopenia and decreased 
muscle strength are also associated with increased health care costs.  Decreased strength 
and power has been linked to several chronic afflictions that are common among the 
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aged.  These include osteoporosis, insulin resistance, and arthritis (Deschenes, 2004).  
The increase in such diseases in the elderly population has contributed to a rise in health 
care costs.  Per capita health care spending has increased dramatically between 1966 and 
2001 (Altman, Tompkins, Eilat, & Gavin, 2003).  It has been estimated that by the year 
2010, approximately $183 billion dollars will be spent on nursing homes by the elderly 
(Greenlund & Nair, 2003). 
Resistance Training 
 Resistance training interventions have proven useful in the elderly population, 
especially in delaying the progression of sarcopenia.  Resistance exercise has been shown 
to increase both strength and muscle fiber size (Frontera et al., 1988; Kryger & Andersen, 
2007; Rogers & Evans; 1993).  Muscle strength has been shown to increase by an 
average of 5% per resistance training session in an aging population (Frontera et al., 
1988).  However, resistance training interventions are not 100% effective.  In rats, a 
decrease in ability of old skeletal muscle to hypertrophy as compared to young skeletal 
muscle has been shown (Degens & Alway, 2003).  In addition, hypertrophy is decreased 
in aged skeletal muscle (Hortobagyi et al., 1995).  This decrease in hypertrophy in the 
elderly population occurs in fast-twitch muscle fibers (Hortobagyi, 2005; Kosek et al., 
2006; Thompson, 1994; Thomson & Gordon, 2005, 2006).  Similar findings have been 
recorded even with the introduction of chronic overload in rats (Blough & Linderman, 
2000; Thomson & Gordon, 2005).  Despite resistance exercise, inhibition of gains in 
force production with age in humans has been shown (Korhonen et al., 2006).  
Additionally, not all of the muscle mass lost through the aging process can be recovered 
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through an intervention. Once lost, fast twitch muscle fibers cannot be recuperated with 
resistance training. 
Protein Degradation 
 Muscle protein degradation (MPD) occurs continuously within prokaryotic and 
eukaryotic cells.  It is the process by which cells are continuously broken down (Viana et 
al., 2008), and leads to a decrease in muscle mass and muscle fiber size if MPD is greater 
than muscle protein synthesis.  In a young, growing individual, protein synthesis 
generally equals or occurs at a more rapid rate than protein degradation.  This leads to an 
increase in muscle strength and muscle hypertrophy, especially with the aid of resistance 
training (Kryger & Andersen, 2007; Rogers & Evans, 1993; Trappe et al., 2000).  There 
is an increase in protein degradation at rest in the older population (Drummond, Miyazaki 
et al., 2008). 
Resistance Exercise Response 
 As a person ages, there is a shift in the balance between protein synthesis and 
protein degradation in response to resistance exercise training (Gordon et al., 2008).  
Protein degradation has also been shown to be higher both at rest and after resistance 
exercise in both old versus young rats (Tamaki et al., 2000) and humans (Kumar et al., 
2009).  Higher protein degradation in muscle cells results in greater muscle atrophy and 
decreased muscle strength that is associated with sarcopenia in the elderly population 
(Mitch & Goldberg, 1996).  Moreover, a greater protein degradation response to 
resistance exercise in the elderly also likely contributes to the diminished muscle growth 
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observed in response to resistance exercise training in that population (Kosek et al., 
2006). 
Upstream Signaling Pathways 
 Protein degradation in skeletal muscle cells is regulated by a number of upstream 
signaling pathways.  One of the main signaling pathways upstream controlling protein 
degradation in skeletal muscle contains atrogin-1 and muscle RING finger 1 (MuRF1), 
both of which are believed to be stimulated by the atrophy-related forkhead box (FOXO) 
transcription factors (especially FOXO1 and FOXO3A) (Zhao et al., 2007) and MuRF1 
(Gordon et al., 2008).  The FOXO transcription factors are a subgroup of the Forkhead 
family of transcription factors.  The FOXO transcription factors are regulated (inhibited) 
by the insulin/PI3K/Akt signaling pathway (Carter & Brunet, 2007).  With 
phosphorylation of FOXO3A at Ser318/321 by Akt (protein kinase B), the FOXO3A 
transcription factor is prevented from translocating to the nucleus of the cell and 
sequestered in the cytosol.  The nucleus is the location where FOXO3A stimulates 
transcription of atrogin-1 and MuRF1 mRNA, which ultimately get translated to atrogin-
1 and MuRF1 proteins and  lead to muscle protein breakdown [as reviewed (Murton, 
Constantin & Greenhaff, 2008)].  Therefore, the phosphorylation of FOXO3A leads to its 
inactivation (due to lack of translocation) and helps lessen protein degradation.  
FOXO3A, and subsequently atrogin-1 and MuRF1, activation during resistance training 
increases with age (Raue et al., 2007; Nakashima & Yakabe, 2007).  The increase in such 
upstream signaling pathways potentially leads to diminished muscle hypertrophy in aged 
skeletal muscle. 
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 On the other side of the balance between protein synthesis and protein 
degradation is mammalian target of rapamyacin (mTOR), which is an upstream signaling 
pathway that regulates both initiation and elongation factors controlling protein synthesis.  
mTOR is activated partly via phosphorylation by Akt with mechanical loading; 
phosphorylation of mTOR can be inhibited by the tuberous sclerosis complex (TSC2) 
(Inoki, Li, Zhu, Wu & Guan, 2002).  Generally, mTOR is stimulated during resistance 
exercise in the young population (Drummond, Dreyer et al., 2008); leading to muscle 
hypertrophy and strength gains (Bodine et al., 2001).  Akt is phosphorylated following 
mechanical loading of the muscle cell to activate mTOR through mTOR phosphorylation 
at Ser2448.  Downstream, mTOR stimulates protein translation through initiation by 
activating 70-kDa ribosomal protein S6kinase (p70s6k) (Inoki, Li, Zhu, Wu & Guan, 
2002).  P70s6k has been shown to inhibit eukaryotic elongation factor 2 kinase (eEF2k) 
(Wang et al., 2001), which activates eEF2 (Ryazanov, Shestakova, & Natapov, 1988).  
Activation of eEF2 can lead to increased translational elongation, which is a process of 
protein synthesis in muscle cells (Horman et al., 2002).  In aged muscle, however, mTOR 
activation is decreased following resistance training (Parkington et al., 2003).  Hindering 
mTOR activation limits this pathway, which decreases protein synthesis and muscle 
hypertrophy, ultimately leading to an increase in protein degradation and lack of muscle 
hypertrophy in aging skeletal muscle. 
AMPK 
 Upstream of mTOR, the FOXO transcription factors, atrogin-1, and MuRF1 lies 
5’-AMP-activated protein kinase (AMPK).  AMPK essentially acts as a sensor of cellular 
energy, responding to increases in the AMP/ATP intracellular ratio (Miranda, Tovar, 
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Palacios, & Torres, 2007).  It attempts to maintain energy stores within the cells to create 
homeostasis.  AMPK hinders protein synthesis (Bolster, 2002), while increasing the 
processes leading to muscle protein degradation (Nakashima & Yakabe, 2007).  
Moreover, there is a fair amount of evidence that AMPK inhibits overload-induced 
muscle hypertrophy (Gordon et al., 2008; Thomson & Gordon, 2005, 2006). 
 AMPK phosphorylation in response to resistance exercise has been shown to be 
elevated with age in humans (Drummond et al., 2008) and rats (Thompson and Gordon, 
2005).  These high levels of AMPK are thought to inhibit mTOR activation, which is 
lower in response to chronic overload (Thompson and Gordon, 2006) or resisted 
contractions in aged muscle (Parkington et al., 2003).  Additionally, AMPK activation 
acts to stimulate protein degradation by enhancing FOXO3/FOXO1 transcription factors, 
and thus stimulating atrogin-1 and MuRF1 (Nakashima & Yakabe, 2007).  FOXO1 and 
FOXO3 may be differentially regulated by AMPK (AMP-activated protein kinase).  In 
vitro, AMPK appears to phosphorylate FOXO3 at several sites, and this occurs more 
efficiently than AMPK’s phosphorylation of FOXO1.  Moreover, AMPK can also inhibit 
Akt’s phosphorylation of FOXO at Ser318/321 and this allows FOXO3A to translocate to the 
nucleus, leading to upregulation of protein degradation pathway components (Greer et al., 
2007).  Skeletal muscle atrogin-1 mRNA content is known to be higher after resistance 
exercise in older vs. younger humans (Raue et al., 2007), and the muscle protein 
synthesis response to resistance exercise is reduced with age (Kumar et al., 2009).  Thus, 
the elevated AMPK response to resistance exercise with age (Drummond et al., 2008), in 
part acting through mTOR, may be one mechanism by which these phenomena occur. 
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Diet, Carbohydrate Intake, and Skeletal Muscle Glycogen Content 
 The diet of the elderly population differs from that of their normal, young 
counterparts.  The elderly consume fewer total calories than the young (Lieberman, 
Wurtman & Teicher, 1989; Wurtman et al., 1988), and do not reach the total daily energy 
intake recommendations (Shabayek & Saleh, 2000).  Additionally, older people generally 
consume less carbohydrates and fats than younger individuals (Lieberman, Wurtman & 
Teicher, 1989; Wurtman et al., 1988). 
The dietary differences between young and elderly populations, especially the 
decrease in carbohydrate consumption, are partially responsible for the decrease in 
muscle glycogen levels in the elderly (Cartee, 1994).  In young individuals, a decrease in 
muscle glycogen is thought to increase AMPK activity, which is higher in the glycogen-
depleted state than in the glycogen-loaded state during aerobic exercise (Wojtaszewski & 
MacDonald et al., 2003).  Additionally, there has been evidence of up to a 26% decrease 
in muscle glycogen content following resistive leg exercise (Tesch et al., 1986), as well 
as a 25% loss in muscle glycogen in the biceps brachii after resistive exercise to muscular 
fatigue (MacDougall et al., 1999).  Thus, the lower muscle glycogen content coupled 
with a resistance exercise-induced further reduction in glycogen content in the elderly 
population may accentuate the increase in AMPK activation seen in response to 
resistance exercise in aged skeletal muscle.  This elevated AMPK activation may 
exacerbate FOXO3A signaling and protein degradation and attenuate muscle hypertrophy 
and strength gains seen in the elderly population (Thomson & Gordon, 2005). 
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Specific Aim 
 Skeletal muscle fiber atrophy has been shown to occur as age increases 
(Hortobagyi et al., 1995).  Additionally, muscle glycogen levels are lower in the elderly 
population than in the young (Cartee, 1994).  Low glycogen and energy levels can 
activate AMPK (Wojtaszewski & MacDonald et al., 2003); AMPK phosphorylation 
following resistance exercise is higher in aged skeletal muscle (Drummond et al., 2008).  
Following resistance exercise, atrogin-1 and MuRF1, which are downstream of 
FOXO3A, are also higher in old individuals when compared to young (Raue et al., 2007; 
Nakashima & Yakabe, 2007).  Akt-stimulated FOXO3A phosphorylation at Ser318/321 
inhibits nuclear translocation and thus inhibits FOXO3A-stimulated atrogin-1, and 
MuRF1 transcription.  FOXO3A phosphorylation at Ser318/321 is attenuated by AMPK 
(Greer et al., 2007).  However, the FOXO3A phosphorylation response to resistance 
exercise in young versus old individuals has not been examined.  Thus, the specific aim 
of this investigation was to examine the FOXO3A Ser318/321 phosphorylation response to 
resistance exercise and its relation to muscle glycogen content and AMPK activation in 
young versus old subjects.  It was hypothesized that FOXO3A Ser318/321 phosphorylation 
would be lower in response to acute resistance exercise in the skeletal muscles of older 
versus younger individuals.  It was further hypothesized that this lower FOXO3A 
phosphorylation response would be related to lower glycogen content and higher AMPK 
activation in the skeletal muscles of older versus younger individuals. 
 CHAPTER II: REVIEW OF LITERATURE 
 
Sarcopenia 
 Sarcopenia, which is the wasting away of skeletal muscle with increasing age, is a 
growing problem in the United States due to the increasing amount of elderly people in 
the population.  After the age of 45, a steady decline in muscle mass is typically observed 
(Hughes et al., 2001).  Sarcopenia has been shown to result in as much as 14% of muscle 
loss and 34% of muscle protein loss between the ages of 25 and 75 (Cohn et al., 1980).  
This clinical issue results in a decreased functional capacity and independence, as well as 
a decrease in the ability for the elderly to complete activities of daily living.  The loss of 
these abilities significantly decreases the quality of life for the aging population.  
Additionally, body mass differences are seen between young and old subjects.  Lean 
body mass has been observed to slowly decrease throughout adulthood.  Lean body mass 
is highest in the third decade, after which it falls slowly for the next two decades, and 
then more rapidly in the elderly.  Body fat content also progressively rises with 
increasing age (Forbes & Reina, 1970). 
Skeletal muscle atrophy occurs due to both a reduction in muscle fiber size and 
number.  This decline occurs in the fast-twitch muscle fibers rather than the slow-twitch 
fibers (Welle, 2002).  Specifically, 20-50% reductions in fiber size of fast-twitch fibers 
have been observed; however, slow-twitch fibers atrophy only 1-25% (Doherty et al., 
1993).  A strength decline in the elderly group of between 20-40% has been reported in 
studies comparing young and old (70-90 years) subjects, with relative loss between 
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women and men being equal (Murray et al., 1985).  This loss of strength strongly 
correlates with loss of skeletal muscle mass.  An approximately 40% decrease in total 
muscle cross sectional area has been observed between the ages of 20 and 60 years 
(Doherty et al., 2002).  The decrease of skeletal muscle size and strength associated with 
sarcopenia may be due to a number of factors, including inadequate nutrients in the diet, 
hormonal changes, and decreased physical activity (Boirie, 2009). 
 It is estimated that approximately one-quarter to one-half of the population of 
both men and women over the age of 65 have sarcopenia (Baumgartner et al., 1998).  
From a practical standpoint, sarcopenia could lead to an increased risk of falls and 
fractures, and eventually a loss of independence (Sayer et al., 2006).  As many as 13.4% 
of men and 16.3% of women over the age of 60 need help getting out of the bed while 
20.3% of men and 30.9% of women in this age range have difficulty walking up a flight 
of only 10 steps.  These percentages continue to increase with age (Ostchega, Harris, 
Hisch, Parsons, & Kington, 2000). 
The decrease in strength associated with sarcopenia has been linked to several 
chronic diseases that commonly occur in the elderly population, including insulin 
resistance and diabetes, arthritis, and osteoporosis (Deschenes, 2004).  Sarcopenia is also 
linked to increased health care costs.  Between 1966 and 2001, per capital health care 
spending has increased dramatically, due in part to afflictions associated with the 
decreased muscle strength and mass of sarcopenia (Altman, Tompkins, Eilat, & Gavin, 
2003).  In 2000, health care costs related to diseases associated with the loss of muscle 
mass with age were around 18.5 billion dollars (Janssen, Shepard, Katzmarzyk & 
Roubenoff, 2004).  With such a prevalence of age-related disability and cost, it is 
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important to examine the mechanism(s) underlying muscle atrophy with age, as well as 
potentially compensatory methods to decrease the effects of increased aging on muscle 
mass and strength. 
Resistance Training 
 Due to the overall loss of strength and muscle fiber size in the elderly, resistance 
training interventions are popular and have proven beneficial to this population.  This 
type of exercise is especially helpful in delaying the process of sarcopenia.  The benefits 
of resistance training include increasing both the cross-sectional area of the muscle fiber 
and muscle strength (Frontera et al., 1988; Kryger & Andersen, 2007; Rogers & Evans; 
1993).  An average of a 5% increase in muscle strength has been shown per resistance 
training session in the aging population (Frontera et al., 1988).  However, although 
clinically significant improvements are seen in the aging with resistance training 
interventions, fast-twitch hypertrophy is greatly reduced in the elderly population 
(Hortobagyi et al., 1995; Kosek et al., 2006; Thompson, 1994; Thomson & Gordon, 
2005, 2006).  This decline in the hypertrophic effect of overloading has also been shown 
in the fast-twitch muscle fibers of aged rats (Thomson & Gordon, 2005).  Slow-twitch 
muscle fibers are more resistant to this loss of effect of resistance training with age than 
fast-twitch fibers (Trappe et al., 2000).  Additionally, elderly females show less muscle 
hypertrophy and strength gains in response to resistance training than elderly males 
(Bamman et al., 2003).  This decrease in the overall effect of resistance training with 
increasing age is a contributing factor of many of the clinical diseases and ailments often 
associated with the elderly, such as sarcopenia, osteoporosis, increased risk of falls, 
broken bones, and orthopedic surgeries. 
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Protein Degradation 
 Muscle protein degradation (MPD) is a catabolic process that occurs naturally and 
continuously in both prokaryotic and eukaryotic cells.  MPD is the break-down and 
deterioration of the proteins comprising muscle cells (Viana et al., 2008).  The major sites 
of intracellular protein degradation are the proteasomes and the lysosomes.  Protein 
degradation is an energy-consuming process that requires ATP (Reggiori & Klionsky, 
2005; Wolf & Hilt, 2004), and has been shown to be stimulated in the lysosomes by high 
stress situations, such as during nutrient depletion (Codogno & Meijer, 2005).  This 
process can lead to muscle atrophy when protein degradation occurs at a higher 
frequency than the rate of protein synthesis.  Protein degradation is increased at rest in the 
older population (Drummond, Miyazaki et al., 2008; Trappe et al., 2004). 
Resistance Exercise Response 
In the skeletal muscle fibers of young men and women, protein synthesis, which 
is the formation of proteins within the muscle, equals or outweighs the effects of protein 
degradation.  This leads to maintenance or an increase in muscle fiber size and strength in 
the young population, especially with the aid of resistance exercise training (Kryger & 
Andersen, 2007; Rogers & Evans, 1993; Trappe et al., 2000).  In the elderly this balance 
is often altered.  Protein degradation has been shown to be higher even after resistance 
exercise in both older rats (Tamaki et al., 2000) and humans (Kumar et al., 2009) than 
their young counterparts.  Thus, this may be one reason why there is less skeletal muscle 
fiber hypertrophy in the elderly population than the young with resistance exercise 
(Kosek et al., 2006; Kryger & Andersen, 2007). 
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Upstream Signaling Pathways 
 There are a number of upstream signaling pathways that stimulate muscle protein 
degradation in mammalian cells.  The pathway associated with atrogin-1 and MuRF1 is 
one of the main signaling pathways upstream that controls muscle protein degradation 
(Gordon et al., 2008).  Atrogin-1, which is an atrophy-related gene, is believed to be 
stimulated by the FOXO transcription factors in skeletal muscle cells (Nakashima & 
Yakabe, 2007; Zhao et al., 2007).  The FOXO transcription factors are a subgroup of the 
Forkhead family of transcription factors and are regulated in part by the insulin/PI3K/Akt 
signaling pathway (Carter & Brunet, 2007).  Akt (protein kinase B) phosphorylates 
FOXO3A at Ser318/321, thus preventing the FOXO transcription factors from entering the 
nucleus of the cell.  Instead, they are then sequestered in the cytosol.  In the cell nucleus, 
FOXO3A stimulates the transcription of atrogin-1 and MuRF1 mRNA.  This mRNA 
ultimately is translated into atrogin-1 and MuRF1 proteins, which lead to muscle protein 
breakdown [as reviewed (Murton, Constantin & Greenhaff, 2008)].  Therefore, the 
phosphorylation of FOXO3A leads to inactivation (due to prevention of translocation) 
and helps lessen protein degradation.  The major contributors of protein degradation, and 
thus muscle fiber atrophy, are the FOXO1 and FOXO3 transcription factors (Zhao et al., 
2007).  The activation of FOXO3A has been shown to stimulate atrogin-1, as well as 
MuRF1, and to cause dramatic atrophy in the skeletal muscle of rats (Sandri et al., 2004).  
MuRF1 expression has been shown to increase under catabolic conditions (Bodine et al., 
2001). FOXO3A, atrogin-1, and MuRF1 mRNA levels during resistance exercise training 
is increased in the elderly (Raue et al., 2007; Nakashima & Yakabe, 2007).  Stimulation 
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of FOXO3 results in both activation of autophagy and lysosomal proteolysis (Zhao et al., 
2007). 
Autophagy and lysosomal proteolysis is mediated by a group of autophagy-
specific gene kinases (ATG).  LC3B, or LC3B-II (light chain 3B), which is also known as 
ATG 8, is a member of this family, and is the active isoform that is formed from the 
cleavage of cytosolic LC3-I (microtubule-associated protein 1 light chain 3) during 
autophagy.  LC3B-II is used as a marker of increased autophagy.  The processes of 
autophagy and lysosomal proteolysis contribute to the increase in muscle cell atrophy and 
strength loss associated with sarcopenia in aging skeletal muscle (Zhao et al., 2007). 
 On the other hand, mammalian target of rapamyacin (mTOR) is an upstream 
signaling pathway associated with protein balance.  The mTOR pathway particularly 
controls protein synthesis response to loading, and ultimately muscle hypertrophy 
(Bodine et al., 2001).  mTOR is activated partly via phosphorylation by Akt with 
mechanical loading (Inoki, Li, Zhu, Wu & Guan, 2002).  However, mTOR also 
suppresses protein degradation.  In normal, young individuals, mTOR is stimulated 
during acute resistance exercise (Drummond & Dreyer et al., 2008).  This leads to 
stimulation of protein synthesis, as well as both muscle hypertrophy and strength gains in 
this population (Bodine et al., 2001; Thomson & Gordon, 2006).  Pharmacological 
blockade of mTOR signaling inhibits resistance exercise-induced protein synthesis in rats 
(Kubica, Bolster, Farrell, Kimball, & Jefferson, 2005) and humans (Drummond, Dreyer 
et al., 2008) and inhibits chronic overload-induced muscle hypertrophy (Bodine et al., 
2001).  In the elderly, mTOR activation is decreased (Parkington et al., 2003; Thomson & 
Gordon, 2006).  mTOR phosphorylation can be deactivated by activation of the tuberous 
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sclerosis complex (TSC) pathway (Inoki, Zhu & Guan, 2003).  mTOR is inhibited 
through TSC2 phosporylation at Thr1227 and Ser1345.  This causes TSC2 activation (Inoki, 
Zhu & Guan, 2003) to inhibit protein synthesis to save energy stores within the muscle 
cell.  Additionally, mTOR deactivation increases autophagy and lysosomal proteolysis, 
and thus, increases muscle atrophy (Zhao et al., 2007).  Protein degradation pathways are 
more elevated in the elderly following resistance exercise than in the young (Raue et al., 
2007; Trappe et al., 2004).  This can ultimately lead to an increase in sarcopenia in the 
elderly population. 
AMPK 
 5’-AMP-activated protein kinase (AMPK) lies upstream of mTOR, the FOXO 
transcription factors, atrogin-1, and MuRF1.  AMPK is has been dubbed a metabolic 
master switch capable of sensing cellular energy disturbances and restoring ATP stores 
(Winder & Hardie, 1999).  A decrease in the cellular AMP/ATP intercellular ratio 
stimulates AMPK (Miranda, Tovar, Palacios, & Torres, 2007), which attempts to create 
homeostasis within the cell by maintaining energy stores.  AMPK is activated by 
processes that either decrease production of ATP or processes within the cell that 
increase utilization of ATP, such as hypoxia or skeletal muscle contraction (Hardie, 
Hawley, & Scott, 2006).  For example, AMPK activation occurs in response to low 
glucose levels within the cell (Salt, Johnson, Ashcroft & Hardie, 1998).  Low glycogen 
and energy levels, even at rest or during aerobic exercise, can activate AMPK 
(Wojtaszewski & MacDonald et al., 2003).  Once activated, AMPK inhibits energy 
consuming pathways.  It acts to promote ATP production through glycolysis.  This 
increases glucose uptake and fatty acid oxidation while inhibiting other energy taxing 
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processes within the cell (Hardie, Hawley & Scott, 2006).  AMPK ultimately hinders 
protein synthesis, which is an energy expensive process; thus, AMPK inhibits the 
processes that lead to muscle hypertrophy and gains in muscle strength, while increasing 
the processes leading to muscle protein degradation (Nakashima & Yakabe, 2007).   
 There is a negative correlation between AMPK phosphorylation and hypertrophy 
in overloaded rat skeletal muscle (Thomson & Gordon, 2005).  Additionally, AMPK 
activity at rest and during overload have been shown to be higher in old versus young rat 
muscle (Drummond et al., 2008); similar observations have been made in humans 
following a bout of acute resistance exercise (Drummond, Dreyer et al., 2008).  This 
elevated AMPK activity is seen in fast-twitch muscle, but not in slow-twitch muscle 
fibers (Thomson & Gordon, 2005). 
The high levels of AMPK phosphorylation and/or activity found in aged skeletal 
muscle likely act to inhibit mTOR activation through tuberous sclerosis complex (TSC2) 
phosphorylation.  This causes TSC2 activation.  The TSC pathway inhibits mTOR 
phosphorylation at Ser1345 (Inoki, Zhu & Guan, 2003).  This site is usually the location of 
Akt phosphorylation, which activates mTOR with mechanical loading of the muscle cell 
(Inoki, Li, Zhu, Wu & Guan, 2002).  The activation of TSC2 and deactivation of mTOR 
hinders protein synthesis and thus prevents a decrease of energy stores within the cell 
(Parkington et al., 2003). 
Additionally, AMPK activation acts to stimulate protein degradation by 
enhancing the FOXO3/FOXO1 transcription factors, and thus stimulates atrogin-1 and 
MuRF1 (Nakashima & Yakabe, 2007).  AMPK can cause FOXO3A to translocate into 
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the nucleus of the cell, where activates the transcription of atrogin-1 and MuRF1 into 
mRNA.  This mRNA can become atrogin-1 and MuRF1 protein, which ultimately lead to 
protein degradation (Greer et al., 2007).  Since AMPK levels have shown to be higher in 
aged skeletal muscle (Drummond, Dreyer et al., 2008), this may be responsible for the 
increased protein degradation and decreased protein synthesis, and consequently the 
muscle atrophy and sarcopenia, often present in the older population.  Additionally, 
higher AMPK levels in aged skeletal muscle may be responsible for diminished muscle 
fiber hypertrophy with overload after resistance training in the elderly (Kosek et al., 
2006). 
Diet and Carbohydrate Intake 
 The diet of the elderly has been shown to differ from of the normal young 
population.  The elderly consume fewer total calories than the young (Furuyama et al., 
2003; Lieberman, Wurtman & Teicher, 1989; Wurtman et al., 1988).  An inverse 
relationship has also been shown between dietary intake and age in the elderly population 
(Sonn, Rothenberg & Steen, 1998).  Many elderly adults do not even consume the 
recommended total daily energy intake (Shabayek & Saleh, 2000).  This population also 
generally consumes significantly less carbohydrates and fats than their younger 
counterparts (Lieberman, Wurtman & Teicher, 1989; Wurtman et al., 1988).  This 
decreased carbohydrate consumption is both in an absolute sense and when consumption 
is adjusted for differences in body weight (Wurtman et al., 1988). 
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AMPK and Glycogen 
 The diet of the elderly population, especially in respect to the decrease in 
carbohydrate consumption by this age group, is partially responsible for a decrease in 
muscle glycogen levels with increased age (Cartee, 1994).  In young subjects a decrease 
in muscle glycogen is thought to increase AMPK activity levels, both at rest and with 
resistance exercise, because AMPK activity is higher in the glycogen-depleted state than 
in the glycogen-loaded state (Wojtaszewski & MacDonald et al., 2003) due to allosteric 
and phosphorylation effects (Greer et al., 2007).  Additionally, there has been evidence of 
up to a 26% decrease in muscle glycogen content following resistive leg exercise (Tesch 
et al., 1986), as well as a 25% loss in muscle glycogen in the biceps brachii after resistive 
exercise to muscular fatigue (MacDougall et al., 1999).  Muscle glycogen content 
following resistive exercise has not been studied in the elderly population, but it would 
follow that since aged skeletal muscle has lower glycogen content than young skeletal 
muscle, the further decrease in muscle glycogen following resistance exercise may 
exacerbate the already elevated AMPK phosphorylation and activity in aged muscle after 
resistance exercise. 
 
Specific Aim 
 Muscle fiber atrophy has been shown to increase with age (Hortobagyi et al., 
1995), and muscle fiber hypertrophy with resistance training or other overloading 
paradigms is diminished with increasing age (Kosek et al., 2006; Thomson & Gordon, 
2005).  This decrease in strength and fiber size may be partially due to a decrease in 
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protein synthesis rate, (Drummond, Dreyer et al., 2008) as well as an increase in muscle 
protein degradation in the elderly population (Kumar et al., 2009).  Protein degradation is 
higher in aged skeletal muscle following resistance exercise than in young (Raue et al., 
2007; Trappe et al., 2004); protein synthesis is decreased in the elderly population after 
resistance training (Drummond, Dreyer et al., 2009).  Higher AMPK phosphorylation and 
activity in aged skeletal muscle in response to overload and/or resistance training has 
been shown in rats (Thomson et al., 2009) as well as humans (Drummond, Dreyer et al., 
2008), and AMPK lies upstream of protein degradation.  Nutritional differences and a 
decrease in muscle glycogen content with increased age have also been observed (Cartee, 
1994).  Additionally, a decrease in muscle glycogen leads to an increase in AMPK 
activity.  Following resistance exercise, atrogin-1 and MuRF1 mRNA, which are 
downstream of FOXO3A, are also higher in old individuals when compared to young 
(Raue et al., 2007; Nakashima & Yakabe, 2007).  Phosphorylation of FOXO3A at 
Ser318/321 is stimulated by Akt.  This inhibits nuclear translocation of FOXO3A, and thus 
prevents FOXO3A from transcribing atrogin-1 and MuRF1 into mRNA.  This process is 
attenuated by AMPK (Greer et al., 2007).  Therefore, the specific aim of this 
investigation was to examine the FOXO3A Ser318/321 phosphorylation response to 
resistance exercise and its relation to muscle glycogen content and AMPK activation in 
young versus old subjects. 
It was hypothesized that FOXO3A Ser318/321 phosphorylation would be lower in 
response to acute resistance exercise in the skeletal muscles of older versus younger 
individuals.  It was further hypothesized that this lower FOXO3A phosphorylation 
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response would be related to lower glycogen content and higher AMPK activation in the 
skeletal muscles of older versus younger individuals. 
 
 CHAPTER III: METHODS 
 
Subjects 
 Participants in this study consisted of 7 young subjects (4 male and 3 female) and 
11 old subjects (5 male and 6 female).  Young subjects ranged in age from 18 to 30 years 
of age, while the old subjects were between the ages of 55 and 85 years.  The subjects are 
all healthy, lean men and women with no reported previous cardiovascular disease, 
diabetes, or hypertension.  None of the participants were on medications that alter 
glucose regulation.  All subjects are non-smokers.  Each of the subjects was screened 
prior to the study to determine age, height, weight, body mass index (BMI (kg/m2)), 
medical history, and exercise history.  Participants were recruited through the posting of 
flyers, word of mouth, and email to East Carolina University faculty and staff.  This study 
was approved by the East Carolina University Institutional Review Board for the Use of 
Human Subjects (See Appendix A). 
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Table 3.1.  Subject Characteristics. 
 
   Young Adults (n=7)        Old Adults (n=11) 
Age (years)          21.7 + 2.1                      67.0 + 8.6 
BMI (kg/m2)          23.5 + 3.05               29.0 + 3.2 
Body Fat (%)          21.9 + 5.0              32.6 + 4.0* 
Weight (kg)          75 ± 14               85 ± 11* 
Table 3.1. Body mass index (BMI) was not significantly different between groups.  The 
young and old groups differed significantly (*) in body fat (%) and weight (kg).  
Significance was set at p < 0.05. 
 
Experimental Design 
The purpose of this investigation was to examine the FOXO3A Ser318/321 
phosphorylation response to resistance exercise and its relation to muscle glycogen 
content and AMPK activation in young versus old subjects. 
It was hypothesized that FOXO3A Ser318/321 phosphorylation would be lower in 
response to acute resistance exercise in the skeletal muscles of older versus younger 
individuals.  It was further hypothesized that this lower FOXO3A phosphorylation 
response would be related to lower glycogen content and higher AMPK activation in the 
skeletal muscles of older versus younger individuals. 
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Table 3.2. Subject Visitations 
Initial Visit (non-fasted) 
 
1) Informed consent & medical history 
2) Height and weight measurements 
3) 4-site skinfold measurements 
4) 10-repetition maximum 
determination 
 
Experimental Session (overnight fast) 
Exercise Session 
- Bilateral leg extension 
- 3 warm-up sets (50, 70, & 90% of 
10RM) 
- 3 sets to failure (100% of 10RM) 
Muscle Biopsy – alternating legs 
       - pre-exercise, immediately post (0  
         min), 60 min, & 120 min post 
Table 3.2. 10-repetition maximum (10RM) was determined using the leg extension 
machine in the FITT building at East Carolina University.  The warm-up sets consisted of 
10 repetitions, 5-7 repetitions, and 3-5 repetitions for each respective set (50, 70, and 
90% of the estimated 10RM).  The 0 minute time point was immediately (within 60-90 
seconds) following the resistance exercise.  60 minutes and 120 minutes post are obtained 
1 and 2 hours following the 0 minute post exercise biopsy, respectively. 
 
 
Initial Visit 
 The first session was performed in the Fitness Instruction, Testing, and Training 
(FITT) building at East Carolina University.  The initial visit consisted of an initial 
screening, baseline measurements, familiarization with the resistance exercise equipment, 
and determination of a 10-repetition maximum (10RM) on the Cybex leg extension 
machine for each participant. 
During the initial visit, participants filled out an informed consent, medical 
history, and a 1-day dietary recall.  Height and weight was obtained, followed by 4-site 
skinfold measurements, which was taken at the bicep, tricep, suprailiac, and subscapula.  
Body fat density was estimated for each participant using the Durnin and Womersley 
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skinfold assessment and body density formula ([495/(l.l714 – 0.063 * LOG[sum of 
skinfolds] – 0.000406 * [age]) – 450]) (Durnin & Womersley, 1974). 
 Following the initial assessment and measurements, the 10-repetition maximum 
was determined on the Cybex Leg Extension machine.  Subjects were acquainted with the 
leg extension machine in order to reduce the likelihood of injury or cardiovascular events.  
Prior to the 10RM testing, participants were asked to predict the maximum amount of 
weight they can lift 10 times.  Half of this amount was used as a warm-up.  After 
completion of the warm-up, the weight was increased by 5-20 pounds, depending upon 
the performance of the individual.  Each set consisted of 10 repetitions, followed by a 1-2 
minute rest interval.  Completion of testing occurred when subjects were unable to 
complete more than 10 repetitions.  This amount was the participant’s 10RM. 
 Before the end of the initial visit, subjects were given an information sheet that 
provided guidelines for the 1-2 week period prior to the experimental session.  Subjects 
were instructed to refrain from exercise and donating blood throughout the duration of 
the study.  Additionally, for the 2 days prior to the experimental session, participants 
were directed to refrain from drinking alcohol, moderate caffeine intake, and drink 64-oz. 
of water daily.  Some older subjects initially chosen to be in a high carbohydrate group 
were counseled on food choices to increase carbohydrate intake prior to the experimental 
session (see “Failed Attempt at Dietary Intervention” for more details).  On the night 
preceding the experimental session, participants were asked to fast for at least 12 hours 
prior to reporting to the laboratory.  On the day of the experimental session, participants 
were instructed to drink 16-oz. of water before coming into the laboratory, and to wear 
comfortable exercise clothing. 
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Failed Attempt at Dietary Intervention 
 All of the young subjects and seven of the old subjects were instructed to continue 
with the normal eating habits throughout the study.  In an initial experimental attempt to 
enhance muscle glycogen content in some older individuals, four old subjects were 
instructed to eat a diet high in carbohydrates for 3 days prior to the experimental session.  
Subjects were counseled on food choices and given food guidelines to assist with dietary 
choices during the initial visit.  When given free food choices in a controlled 
environment, elderly subjects generally ingest approximately 30% of their total calories 
from carbohydrates and 50% from fat (Wurtman, 1988).  Since the main goal of the study 
design was to enhance skeletal muscle glycogen content, the high carbohydrate diet 
attempted to guide the older subjects to eat 60-70% of their total calories from 
carbohydrates.  Additionally, this diet attempted to decrease calories from fat accordingly 
(protein intake will remain unaltered if possible).  Dietary logs for all study subjects were 
maintained in the 3 days prior to the experimental session.  These logs were analyzed via 
Nutritionist ProTM software to assess caloric intake and dietary composition. 
 Unfortunately, the older subjects intended to maintain a high carbohydrate diet 
did not successfully accomplish this, either due to low adherence or lack of nutritional 
choice knowledge.  Dietary analysis of food logs showed no difference between the old 
“ad lib” group and the high carbohydrate old group.  Table 3.3 presents the diet 
breakdown of both old groups of subjects, as well as the young subjects.  Since dietary 
composition was virtually identical between the old “ad lib” group and the group 
intended for high carbohydrate, all old subjects were combined for all analyses in this 
study. 
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Table 3.3.  Young vs. Old Dietary Intake 
 
   Total kcal/day       % kcal Protein             % kcal Carb          % kcal Fat 
 
All Young (n=7)  1608.4 + 486.4              15.3 + 5.4      52.9 + 12.1        29.7 + 6.5 
All Old (n=9)         1994.4 + 308.9            17.8 + 2.9      47.6 + 10.5        34.6 + 9.5 
 
Old “Ad Lib”* (n=5)  1994.7 + 579.4            18.2 + 2.7      47.0 + 11.8        34.8 + 11.2 
Old High CHO (n=4) 1993.9 + 137.6                17.2 + 3.5      48.4 + 10.4        34.4 + 8.5 
 
Table 3.3 represents the breakdown of dietary intake between the Young and Old Groups, 
and in the two old subgroups.  Old “Ad Lib” are the older subjects with no dietary 
restrictions.  The Old High CHO group was instructed to eat a high carbohydrate diet.  
Upon dietary analysis, it was discovered that the groups were very comparable in the 
percentage of carbohydrates consumed. 
 
* The data from the Old “Ad Lib” group is a majority sub-sample of the entire group of 
7.  Dietary logs were not obtained from all subjects in this group. 
 
 
 
 
 
Experimental Session 
One to two weeks following the initial visit, subjects came into either the Brody School 
of Medicine, room 3S08, or The East Carolina Heart Institute, after an overnight fast for 
the exercise session.  The 1-2 week waiting period was used as a recovery period in the 
event that muscle soreness is caused by the 10RM testing at the initial visit, as this may 
skew the results during the exercise session.  The 10RM testing was used for the 
resistance exercise bout in the experimental session in an attempt to stimulate AMPK and 
the downstream signaling pathways.  A muscle biopsy was obtained prior to exercise for 
pre-exercise measurements, immediately post exercise (after completion of the final 
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resistance exercise set and completion of preparation for the biopsy), one hour following 
the immediately post-exercise biopsy, and two hours after taking the immediately post-
exercise biopsy.  Biopsy time points are based upon the results of Drummond et al. 
(Drummond, Dreyer et al., 2008), which concluded that AMPK phosphorylation is 
greater in old versus young men by 1 hour post-resistance exercise, and continues until at 
least 2 hours post resistance exercise.  A figure of the timeline for the experimental 
session is presented in Figure 3.1. 
 
 
 
 
Timeline of Experimental Session 
 
 
     Pre-Ex                    0P               1P        2P 
                pre-exercise          immediately post-      1-hour post             2-hour post 
     biopsy            exercise biopsy          biopsy    biopsy 
               
                
 
Figure 3.1. Timeline of events for the experimental session for each subject.  Pre-
Ex is the period prior to the exercise session.  0P is the exercise session.  1P is 60 
minutes after the resistance exercise session.  2P is 120 minutes after the 
resistance exercise session. 
 
 
 
Exercise 
28 
 
Acute Resistance Exercise 
 The acute resistance exercise was performed on the Cybex Leg Extension 
machine after the pre-exercise muscle biopsy was obtained.  The exercise session first 
consisted of a warm-up set of 50% of the predetermined 10RM.  A 1.5 minute rest 
interval was given, followed by a second warm-up set consisting of 5-7 repetitions 
performed at 70% of the predetermined 10RM.  Following an additional 1.5 minute rest 
interval, the final warm-up set consisted of 3-5 repetitions at 90% of the predetermined 
10RM.  The standard 1.5 minute rest interval was given, and then each participant began 
the three working sets using the predetermined 10RM.  Each working set was performed 
until failure; both the first and second working set was followed by a 1.5 minute rest 
interval.  Once a participant reached failure, they were encouraged verbally to complete 
1-3 forced repetitions with the assistance of the investigator directing the exercise 
session. 
Muscle Biopsies 
 All biopsy procedures were performed under aseptic conditions.  The vastus 
lateralis muscle was located on each subject, and the area was marked and shaved if 
necessary.  The area was sterilized with iodine swabs and draped with a sterile field.  
Cold spray was administered to numb the area and approximately 5 mL of local 
anesthetic (1% Lidocaine) was injected into the biopsy site subcutaneously along the 
vastus lateralis.  A small incision of approximately ¼ inch was made on the skin through 
the fascia of the vastus lateralis muscle using a No. 11 scalpel.  A 5-mm Bergstrom 
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needle was used for muscle biopsies.  Sterile procedure and suction was then applied in 
order to maximize the amount of muscle extracted during each biopsy. 
 Immediately following each biopsy, direct pressure and ice was applied to the 
procedure site to subside bleeding.  Once bleeding ceased, a steri strip bandage was 
applied to hold the incision site together, followed by a band aid, a Tegaderm patch, and 
a pressure wrap.  This particular set-up was to allow proper healing and aid in a 
decreased likelihood of scarring at the biopsy site. 
 Preparation for the first two muscle biopsies occurred prior to exercise on each 
leg.  Subsequent biopsies used alternating legs, with the first and third biopsies occurring 
on the same side.  Following the pre-exercise biopsy, the participant performed the acute 
resistance exercise session.  Directly after the resistance exercise bout, the subject was 
moved to a bed where the immediately post-exercise biopsy was taken.  After 60 minutes, 
the third muscle biopsy was taken approximately 5cm proximal to the initial biopsy site.  
A final biopsy was taken at 120 minutes post-exercise from the vastus lateralis 
approximately 5cm from the second biopsy site. 
 The muscle tissue was divided following removal.  One portion was immediately 
oriented for cross-sectional alignment and mounted in a mixture of tragcantham gum and 
OCT compound.  Following embedding in the OCT mixture, samples were frozen in 
isopentane chilled in liquid nitrogen.  The second portion of the muscle tissue was placed 
into a cryovial and flash frozen in liquid nitrogen for later western blot analyses.  
Samples were then stored at 80 degrees Celsius until they were analyzed. 
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Sample Analysis 
Analysis of Muscle Glycogen Content 
 Analysis of muscle glycogen content occurred using a method modified from a 
combination of methods derived from Passonneau and Lauderdale (1974), Passonneau 
and Lowry (1993), and Roy and Tarnopolsky (1998).  Specifically, 5-15 mg of each 
subject’s muscle sample was homogenized on ice in 53.3 volumes (3 mg/160 µL) of 0.1 
M NaOH with a ground glass homogenizer.  A 100-µL aliquot of each homogenate was 
heated for 20 minutes at 80ºC in order to destroy any free glucose.  Afterwards, the pH of 
each sample was neutralized with 100 µL of 0.2 M acetic acid and vortexing.  Next, two 
50-µL aliquots of each sample were placed into duplicate tubes containing 200 µL of 0.1 
M sodium acetate buffer (0.05 M acetic acid; 0.05 M sodium acetate, pH 4.6-4.7).  All 
remaining steps were performed in duplicate.  To obtain free glucosyl units, 
glyogenolysis was accomplished by adding 10 µL of amyloglucosidase (10 µg/mL in 20 
mM Tris buffer and 0.02% bovine serum albumin, pH 7.5; specific activity = 25.9 U/mg; 
Sigma-Aldrich # A7420, St. Louis, MO), vortexing, and then incubating at room 
temperature for 1 hour.  Samples were clarified of any precipitate that remained in 
suspension by centrifugation at 16000 x g for 5 minutes.  A glucose assay that is 
commercially available (based upon hexokinase and glucose-6-phosphate dehydrogenase 
reactions; Sigma-Aldrich # GAHK20) was then performed to determine free glucosyl 
units in each sample.  The glycogen content (µg/mg wet weight) of the original muscle 
samples was then determined by comparison to a standard curve made with type III 
glycogen from rabbit liver (Sigma-Aldrich # G8876).  This was treated in exactly the 
same manner as the muscle samples starting with the NaOH step. 
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Western Blotting Analysis for AMPK Phosphorylation, ACC, FOXO3A Protein, and 
MuRF1 
AMPK, ACC, FOXO3A protein and phosphorylation measurements, and MuRF1 
were all analyzed using the Western blot analysis method.  The primary antibodies are 
commercially available: anti-AMPK [Cell Signaling Technology (CST); Danvers, MA; 
Cat. # 2532], rabbit monoclonal anti-phospho-AMPK (CST; Cat. # 4188), anti-acetyl 
CoA Carboxylase (streptavidin-HRP, GE Life Sciences, RPN1231), anti-MuRF1 (CST; 
Cat # 4305), anti-phospho-FOXO3A (CST; Cat # 9465), and anti-phospho-Acetyl CoA 
carboxylase (Millipore Corporation; Temecula, CA; Cat. # 07-303).  Phospho-Acetyl 
CoA is an in vivo indicator of AMPK activity.  A small piece of each frozen muscle 
biopsy sample was homogenized using a buffer that consisted of 50 mM HEPES (pH 
7.4), 0.1% Triton X-100, 4 mM EGTA, 10 mM EDTA, 15 mM Na4P2O7•10H2O, 100 
mM ß-glycerophosphate, 25 mM NaF, 50 µg/ml leupeptin, 50 µg/ml pepstatin, and 33 
µg/ml aprotinin.  All homogenizations were performed in ice to prevent excessive heat 
build-up.  Heat build-up can denature proteins. Additionally, all homogenizations were 
performed using a ground glass homogenizer that utilizes a variable speed motor. 
Assessment of the homogenates for protein concentration was carried out in 
triplicate using a modification of the Lowry procedure (DC Protein Assay, Bio-Rad, 
Hercules, CA, USA).  Total muscle protein homogenates were mixed in a loading buffer 
(50 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 2% ß-mercaptoethanol, 0.1% 
bromophenol blue) at a dilution of 1 mg per ml.  The mixture was then boiled for 5 
minutes.  Proteins were separated by a 4-7.5% gradient sodium dodecyl sulfate-
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polyacrylamide gel electrophoresis (SDS-PAGE).  Gel electrophoresis occurred for 1.5 
hours at 4˚C on a PVDF membrane at 100V in a transfer buffer.  The buffer contained 25 
mM Tris-base pH~8.3, 192 mM glycine, and 20% methanol.  Ponceau S, stained the 
membranes.  Following staining, they were dried and scanned into a digital image.  This 
image allows measurement of the relative total protein loaded into each label through the 
gray scale integrated optical density of the full length of each individual lane.  
Membranes were then blocked for one hour at room temperature in blocking buffer, 
consisting of 5% nonfat dry milk in TBS-T (20 nM Tri-base, 150 mM NaCL, 0.1% 
Tween-20) pH 7.5.  Following that step, the membranes were incubated in the primary 
antibody diluted in 1% bovine serum albumin in TBS-T overnight at 4˚C.  Primary 
antibody dilutions consisted of anti-phospho-AMPK:  1/4000; anti-AMPK:  1/1000; anti-
phospho-ACC:  1/1000; anti-ACC:  1/1000; anti-FOXO3A: 1/1000; anti-MuRF1: 1/1000.  
Membranes were then washed 4 times with 5 minutes between each wash in TBS-T, 
incubated in secondary antibody in blocking buffer for an hour while at room 
temperature.  There was then another round of 4 x 5 minutes wash periods in TBS-T.   
Following the last wash, detection of the HRP activity occurred using a 
chemiluminescence reagent (Amersham, Piscataway, NJ) and exposure to 
autoradiographic film (Classic Blue Sensitive; Midwest Scientific, St Louis, MO, USA).  
The integrated optical densities (IODs) were quantified by densitometry and calculation 
of the concentration of the antigen present in each muscle as the IOD was normalized to 
units of total muscle protein initially loaded on the gel.  Correction for the grayscale IOD 
of each total lane was evaluated on the image of the Ponceau stain that was previously 
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captured.  The HRP-conjugated anti-rabbit secondary antibody was acquired from 
Amersham. 
Statistics 
 An analysis of variance (ANOVA) with repeated measures was used to analyze 
the differences between and within groups over time for glycogen and all western blot 
data.  Fischer’s LSD post-hoc test for measurement of post-hoc differences was utilized 
where necessary.  All correlational analyses were performed as Pearson Product-moment 
correlations.  Subject characteristic data were analyzed using independent samples t-tests.  
Significance was set at an alpha level of p < 0.05. 
 CHAPTER IV:  RESULTS 
 
Subject Strength and Work Volume 
All subjects completed both the initial visit and experimental session.  Exercise 
performance was measured using both the total and relative volume of exercise for each 
group (Y and O).  Total volume was determined by multiplying the total amount of 
weight lifted by the repetitions for each work set (excluding warm-up sets) during the 
experimental session.  Relative volume was determined by taking the total volume and 
divided by each individual’s fat-free mass (kg).  Data are presented in Table 4.1 (below).  
Additionally, 10-RM (kg) values for young and old groups were broken down by gender 
(Table 4.2). 
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Table 4.1.  Assessment of 10-repetition Maximum Strength and Workout Volume 
Between Young Adults (Y) and Old Adults (O) 
       
 Y (n=7)        O (n=11) 
Estimated 10 RM (kg) *   48 ± 10            32 ± 14 
Estimated total volume  1644.6 ± 195             1131.8 ± 395 
(kg resistance x repetitions)    
Relative volume *   28 ± 1.9            19 ± 4.9 
(kg resistance/kg FFM) 
 
*A significant difference between young and old groups was found (p < 0.05).  Total 
volume (kg resistance) was calculated to assess the absolute amount of weight lifted 
during the working sets by each subject with the equation:  Total volume = [(resistance set 
1(kg) x repetitions set 1) + (resistance set 2(kg) x repetitions set 2) + (resistance set 3(kg) x 
repetitions
 set 3)].  Note that the total volume calculations are only an estimate, as the last 
1-3 repetitions of each working set were usually assisted to varying degrees in order to 
help the subject complete the repetitions.  Total volume was normalized to fat free mass 
in order to show the relative amount of weight lifted:  relative volume = total volume (kg 
resistance) / fat free mass (kg).  All data are presented as means + SEMs. 
 
 
Table 4.2. Estimated 10-RM Breakdown between Genders 
    YM (n=4) YF (n=3) OM (n=5) OF (n=6) 
Estimated 10-RM (kg) 55.4+12.8 38.6+9.9* 40.0+8.5 27.7+9.6* 
All data are presented as Means + SEMs.  *A significant main effect of gender was found 
in estimated 10-RM between young males (YM) and old males (OM) combined vs. 
young females (YF) and old females (OF) combined.  Significance is set at p<0.05. 
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Muscle Glycogen Content 
A significant difference was seen in glycogen content between young and old 
subjects at the pre-exercise time point.  Additionally, there was a significant main effect 
of time points 0P (immediately post-exercise), 1P (1-hour post-exercise) and 2P (2-hours 
post-resistance exercise) for both young and old groups (Figure 4.1).  There was also a 
main effect for percent decrease in glycogen content across all post-exercise time points.  
The young group had a greater drop in glycogen content following the acute resistance 
exercise bout than the old group. 
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Figure 4.1. Mean + SEM glycogen content in young and old subjects.  PRE is the pre-
exercise muscle biopsy, 0P is the immediately post-exercise muscle biopsy, 1P is the 1 
hour post-exercise muscle biopsy, 2P is the 2 hour post-exercise muscle biopsy.  
†Significant (p < 0.05) difference between young and old groups at PRE time point.  
*Significantly lower than PRE within young and old groups independently.  There was 
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also a main effect for percent decrease in glycogen content in young vs. old of time point 
0P, 1P, and 2P (data not shown). 
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AMPK Western Blotting 
A significant increase was found in AMPK phosphorylation at Thr172 versus PRE 
(pre-exercise) in old subjects at the 0P (immediately post-resistance exercise) time point, 
but this was not observed in the young group (Figure 4.2).  No difference was found in 
total AMPK between young and old subjects or at any time point (Figure 4.3).  A 
significant main effect time point for phospho/total AMPK ratio and post-hoc analysis 
showed that time point 0P was elevated versus PRE for young and old groups combined 
(Figure 4.4). 
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Figure 4.2.  Mean + SEM phospho-AMPK in young and old subjects and representative 
blots.  PRE is the pre-exercise muscle biopsy, 0P is the immediately post-exercise muscle 
biopsy, 1P is the 1 hour post-exercise muscle biopsy, 2P is the 2 hour post-exercise 
muscle biopsy.  * Phospho-AMPK was significantly (p < 0.05) elevated above PRE in 
old subjects at the 0P time point. 
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Figure 4.3.  Mean + SEM phospho-AMPK in young and old subjects and representative 
blots.  PRE is the pre-exercise muscle biopsy, 0P is the immediately post-exercise muscle 
biopsy, 1P is the 1 hour post-exercise muscle biopsy, 2P is the 2 hour post-exercise 
muscle biopsy.  Total AMPK showed no significant differences between young and old 
groups, or across any time points. 
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Figure 4.4.  Mean + SEM phospho/total AMPK ratio in young and old subjects.  PRE is 
the pre-exercise muscle biopsy, 0P is the immediately post-exercise muscle biopsy, 1P is 
the 1 hour post-exercise muscle biopsy, 2P is the 2 hour post-exercise muscle biopsy.   
# Phospho/total AMPK ratio showed a significant main effect time point, and post-hoc 
analysis showed that time point 0P was elevated vs. PRE for young and old groups 
combined. 
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ACC Western Blotting 
 Phospho-acetyl CoA carboxylase (ACC) at Ser79 showed a significant main effect 
time point, and post-hoc analysis showed that time points 0P (immediately post-exercise) 
and 1P (1 hour post-exercise) were elevated versus pre-exercise in young and old groups 
combined (Figure 4.5).  The same findings were consistent for total ACC (Figure 4.6) 
and the phospho/total ACC ratio (Figure 4.7). 
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Figure 4.5.  Mean + SEM phospho-ACC in young and old subjects and representative 
blots.  PRE is the pre-exercise muscle biopsy, 0P is the immediately post-exercise muscle 
biopsy, 1P is the 1 hour post-exercise muscle biopsy, 2P is the 2 hour post-exercise 
muscle biopsy.  # Significant (p < 0.05) main effect of time points, and post-hoc analysis 
showed that time points 0P and 1P were elevated vs. PRE for young and old groups 
combined. 
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Figure 4.6.  Mean + SEM total ACC in young and old subjects and representative blots.  
PRE is the pre-exercise muscle biopsy, 0P is the immediately post-exercise muscle 
biopsy, 1P is the 1 hour post-exercise muscle biopsy, 2P is the 2 hour post-exercise 
muscle biopsy.  # Significant (p < 0.05) main effect of time points, and post-hoc analysis 
showed that time points 0P and 1P were decreased vs. PRE for young and old groups 
combined. 
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Figure 4.7.  Mean + SEM phospho (Ser79)/total ACC ratio in young and old subjects.  
PRE is the pre-exercise muscle biopsy, 0P is the immediately post-exercise muscle 
biopsy, 1P is the 1 hour post-exercise muscle biopsy, 2P is the 2 hour post-exercise 
muscle biopsy.  # Significant (p < 0.05) main effect of time points, and post-hoc analysis 
showed that time points at 0P and 1P were elevated vs. PRE for young and old groups 
combined.   
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FOXO3A Western Blotting 
 There were no significant differences observed in phospho-FOXO3A at Ser318/321 
pre- to post-exercise or between young and old subjects at any of the time points (Figure 
4.8).  The percent change from baseline (pre-exercise) of phospho-FOXO3A at Ser318/321 
showed a p-value of 0.17 for the main effect of young versus old subjects across all time 
points (Figure 4.9). 
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Figure 4.8.  Mean + SEM phospho-FOXO3A at Ser318/321 in young and old subjects and 
representative blots.  PRE is the pre-exercise muscle biopsy, 0P is the immediately post-
exercise muscle biopsy, 1P is the 1 hour post-exercise muscle biopsy, 2P is the 2 hour 
post-exercise muscle biopsy.  Phospho-FOXO3A was not significantly different between 
age groups or across any time points. 
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Figure 4.9.  Mean + SEM for percent change of FOXO3A at Ser318/321 from baseline 
(PRE) in young and old subjects.  PRE is the pre-exercise muscle biopsy or baseline, 0P 
is the immediately post-exercise muscle biopsy, 1P is the 1-hour post-exercise muscle 
biopsy, 2P is the 2-hour post-exercise muscle biopsy.  p = 0.17 for main effect of young 
vs. old group across all time points.  
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MuRF1 Western Blotting 
 No significant differences were seen in total MuRF1 in response to exercise or 
between young and old subjects at any time point (Figure 4.10).  For MuRF1 percent 
change from baseline (pre-exercise), there was a p-value of 0.155 for the main effect of 
young versus old subjects across all time points.  In addition, there was a significant main 
effect time point for total MuRF1, and post-hoc analysis showed that time point 2P (2 
hours post-exercise) was decreased versus 0P (immediately post-exercise) for both young 
and old groups (Figure 4.11). 
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Figure 4.10.  Mean + SEM total MuRF1 in young and old subjects and representative 
blots.  PRE is the pre-exercise muscle biopsy, 0P is the immediately post-exercise muscle 
biopsy, 1P is the 1 hour post-exercise muscle biopsy, 2P is the 2 hour post-exercise 
muscle biopsy.  No significant differences were seen in total MuRF1 between young and 
old subjects, or across any time points.   
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Figure 4.11.  Mean + SEM percent change of MuRF1 from baseline (PRE) in young and 
old subjects.  PRE is the pre-exercise muscle biopsy or baseline, 0P is the immediately 
post-exercise muscle biopsy, 1P is the 1 hour post-exercise muscle biopsy, 2P is the 2 
hour post-exercise muscle biopsy.  # Significant (p < 0.05) main effect at time point 2P 
versus 0P in young and old groups combined.  p = 0.155 for main effect of young vs. old 
across all time points.   
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Association of AMPK Activity and Phospho-FOXO3A with Glycogen Content 
 We found a significant, or close to significant, relationship between glycogen 
content and both FOXO3A phosphorylation and the phospho/total ACC ratio at most 
timepoints (Figs 4.12-4.15).  We chose to examine the relationship of glycogen content 
with ACC phosphorylation status rather than AMPK phosphorylation because it is a 
better indicator of AMPK activity (Park et al., 2002).  Higher muscle glycogen content 
was associated with lower phospho/total ACC ratio and higher FOXO3A 
phosphorylation.  P-values were all very close or below the significant value of p < 0.05 
at the PRE, 0P, and 1P timepoints for phospho/total ACC ratio, and at the 0P, and 1P 
timepoints for FOXO3A phosphorylation.  Thus, by increasing muscle glycogen content, 
AMPK activity may be decreased, while phospho-FOXO3A at Ser318/321 may be 
accentuated, potentially lessening the effect on the protein degradation pathway. 
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Figure 4.12.  Relationship between glycogen content and the phospho/total ACC ratio 
(top) and between glycogen content and phospho-FOXO3A (bottom) at the pre-exercise 
time point.  Significance is set at p < 0.05. 
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Figure 4.13.  Relationship between glycogen content and the phospho/total ACC ratio 
(top) and between glycogen content and phospho-FOXO3A (bottom) at the immediately 
post-exercise time point.  Significance is set at p < 0.05. 
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Figure 4.14.  Relationship between glycogen content and the phospho/total ACC ratio 
(top) and between glycogen content and phospho-FOXO3A (bottom) at the one-hour 
post-exercise time point.  Significance is set at p < 0.05. 
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Figure 4.15.  Relationship between glycogen content and the phospho/total ACC ratio 
(top) and between glycogen content and phospho-FOXO3A (bottom) at the two-hour 
post-exercise time point.  Significance is set at p < 0.05.  
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To further investigate the potential effect of pre-exercise muscle glycogen content 
on the phospho-FOXO3A response to resistance exercise, subjects were grouped into 
either a high glycogen (>16 µg/mg) or low glycogen (<12 µg/mg) group regardless of 
age.  The high glycogen group consisted of 5 young and 2 old subjects, while the low 
glycogen group consisted of 2 young and 6 old subjects.  A significant main effect was 
observed in phospho-FOXO3A (Ser318/321) between high and low glycogen content across 
all time points (Figure 4.16).  There was also a significant main effect observed in the 
phospho-FOXO3A (Ser318/321) percent change from baseline across all post-exercise time 
points in high and low glycogen content groups (Figure 4.17). 
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Figure 4.16.  Mean + SEM phospho-FOXO3A (Ser318/321) in high muscle glycogen vs. 
low muscle glycogen groups.  PRE is the pre-exercise muscle biopsy, 0P is the 
immediately post-exercise muscle biopsy, 1P is the 1 hour post-exercise muscle biopsy, 
2P is the 2 hour post-exercise muscle biopsy.  # Significant (p < 0.05) main effect of high 
glycogen group vs. low glycogen group across all time points.   
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Figure 4.17.  Mean + SEM for percent change of FOXO3A at Ser318/321 from baseline 
(PRE) in high vs. low glycogen groups.  PRE is the pre-exercise muscle biopsy or 
baseline, 0P is the immediately post-exercise muscle biopsy, 1P is the 1-hour post-
exercise muscle biopsy, 2P is the 2-hour post-exercise muscle biopsy.  # Significant (p < 
0.05) main effect of high glycogen group vs. low glycogen group across all post-exercise 
time points.  Significance is set at p < 0.05. 
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Association of AMPK Activity and FOXO3A 
 We also examined the relationship between AMPK activity (as indicated by 
phospho/total ACC ratio at Ser79) and phospho-FOXO3A (Ser318/321) pre-exercise (Figure 
4.18), immediately post-resistance exercise (Figure 4.19), 1-hour post-exercise (Figure 
4.20), and 2-hours post-exercise (Figure 4.21).  The observed associations were very 
weakly negative (non-significant) across all four time points. 
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Figure 4.18.  Relationship between the phosphor/total ACC ratio and phospho-FOXO3A 
pre-exercise.  Significance is set at p < 0.05. 
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Figure 4.19.  Relationship between the phospho/total ACC ratio and phospho-FOXO3A 
immediately post-resistance exercise.  Significance is set at p < 0.05.  
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Figure 4.20.  Relationship between the phospho/total ACC ratio and phospho-FOXO3A 
1-hour post-exercise.  Significance is set at p < 0.05.  
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Figure 4.21.  Relationship between the phospho/total ACC ratio and phospho-FOXO3A 
2-hours post-exercise.  Significance is set at p < 0.05.  
 
 
 
 CHAPTER V: DISCUSSION 
 
 The specific aim of this study was to examine the FOXO3A Ser318/321 
phosphorylation response to resistance exercise and its relation to muscle glycogen 
content and AMPK activation in young versus old subjects.  We hypothesized that 
FOXO3A phosphorylation at Ser318/321 would be lower in response to acute resistance 
exercise in the skeletal muscles of older versus younger individuals.  It was further 
hypothesized that this lower FOXO3A phosphorylation response would be related to 
lower glycogen content and higher AMPK activation in the skeletal muscles of older 
versus younger individuals. 
As hypothesized, AMPK phosphorylation at Thr172 was elevated in old 
immediately post-resistance exercise (0P), but not in young.  Nevertheless, although there 
was a significant main effect in the phospho/total AMPK ratio immediately post-
resistance exercise in both young and old groups, there were no differences between age 
groups for ratio.  Additionally, there were no differences between young and old groups 
at any time point in phosphor-acetyl CoA carboxylase (ACC), which is a downstream 
marker of AMPK activity (Hawley et al., 1996).  However, there was a significant 
increase (main effect) at 0P (immediately post-resistance exercise) and 1P (one hour post-
exercise) for both young and old groups compared to pre-exercise.  This significant 
increase was also seen in the phospho/total ACC ratio immediately post-resistance 
exercise and one hour post-resistance exercise in both the young and old group, with no 
significant differences between age groups across any time points for phospho/total ACC 
ratio.   
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 The present AMPK phosphorylation results are in partial agreement with some 
previously published literature.  Research conducted by Drummond et al. (Drummond, 
Dreyer et al., 2008) showed a significant exercise-induced increase in AMPK 
phosphorylation in older subjects at 1 hour and 3 hours following an acute bout of 
resistance exercise, while younger subjects had no such increase.  While our results show 
a significant elevation of AMPK phosphorylation in old subjects immediately post-
resistance exercise, the phosphorylation of AMPK fell to levels comparable to young 
subjects by one hour post-exercise.  Drummond et al. found phospho-AMPK levels to 
remain elevated for a longer period of time (3 hours post-resistance exercise), but did not 
assess the phospho/total AMPK ratio.  A number of factors could have contributed to this 
difference.  Drummond et al. (Drummond, Dreyer et al., 2008) used 8 working sets 
during the acute resistance exercise session, while this study used 3 working sets.  This 
higher and prolonged workload could have contributed to a higher and prolonged AMPK 
phosphorylation response to the leg extension exercise.  This possibility is supported by 
data from Thompson and Gordon (Thompson and Gordon, 2005), who found a higher 
AMPK phosphorylation in old muscle when compared to young both at rest and after 
chronic overload in rats. 
Although the current study found a small age difference in the AMPK 
phosphorylation response to resistance exercise, the ACC phosphorylation response was 
similar between age groups.  In fact, AMPK phosphorylation is not the best indicator of 
AMPK activity.  Glycogen and AMP can bind to AMPK and influence activity by 
impacting the phosphorylation of AMPK, as well as by allosterically influencing AMPK 
activity independent of phosphorylation (McBride et al., 2009; Sanders et al., 2007).  
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ACC is phosphorylated by AMPK at Ser79 (Tong et al., 2009) and is considered a better 
indicator of true in vivo AMPK activity (Park et al., 2002).  This may explain why 
Drummond et al. (Drummond, Dreyer et al., 2008) found no phospho-AMPK increase 
with resistance exercise in young in contrast with their old subjects, while other data from 
the same laboratory (Dreyer et al., 2006) have shown an increase in AMPK activity after 
acute resistance exercise in young subjects.  Likewise, the current investigation found a 
somewhat accentuated AMPK phosphorylation response to resistance exercise in old 
subjects compared to young, while ACC phosphorylation, an indicator of AMPK activity, 
was elevated equally in both age groups and in a more prolonged fashion than AMPK 
phosporylation.  ACC phosphorylation, and phospho/total ACC ratio both showed a 
significant main effect at the immediately post-exercise and the one-hour post-exercise 
time points when compared to the pre-exercise values in young and old groups combined.  
These data indicate that AMPK activation may not have differed between young and old 
individuals in the current investigation. 
A number of factors may have contributed to the lack of difference observed in 
phospho-ACC between age groups in the current study.  Significant differences may not 
have been seen between the young and old groups because the older subjects were 
healthier than the average older adult.  Thus, this group of old subjects may not be 
representative of the general older adult population.  In conjunction with a healthier than 
average older group, it is possible that the young group is not a true representation of the 
young adult population.  The delimitations of the current study excluded individuals who 
participated in regular physical activity.  Therefore, the young subjects in the current 
study may not adhere to as healthy of a lifestyle as the older subjects.  Also, there may 
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have been gender differences in strength and 10-RM that could have played an impact on 
ACC phosphorylation.  However, since male and female subjects characteristics were not 
differentiated in the current study, these differences could have been diminished in the 
group averages.  In addition, potential differences in phospho-ACC between age groups 
may have occurred only in fast-twitch fibers and thus been “masked” by homogenization 
with slow-twitch fibers.  Muscle atrophy and diminished muscle hypertrophy occur in 
fast-twitch muscle fibers, but not slow-twitch fibers (Rogers & Evans, 1993); however, 
both fiber types are mixed in the muscle biopsy samples taken from the subjects.  
Thompson and Gordon (Thompson and Gordon, 2005) observed the highest AMPK and 
ACC results only in fast twitch muscle fibers, but not slow-twitch.  Therefore, the 
mixture of fiber types in the sample could have also played a role in the lack of 
observable differences between phospho-ACC between young and old groups in the 
current investigation. 
Another possible explanation for the lack of differences seen between AMPK and 
ACC (AMPK activity) may be fasting status. All of our subjects came into the 
experimental session following a 12-hour fast.  A study by Combaret et al. (Combaret et 
al., 2005) found that proteolysis was elevated in rat skeletal muscle with increased age; 
however, the highest effects in proteolysis were seen following a meal.  Also, Drummond 
et al. (Drummond, Dreyer et al., 2008) required their subjects to ingest an essential amino 
acid and carbohydrate supplement 1 hour following the resistance training exercise.  
Their use of non-fasted subjects may have had an impact on AMPK phosphorylation 
because AMPK is partially regulated by internal energy stores.  Thus, some age-related 
differences are postprandial.  Therefore, differences in AMPK and AMPK activity may 
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primarily occur following a meal as opposed to the fasted state.  This may also have been 
a reason why we saw no age-related differences in FOXO3A in the current investigation.  
FOXO3A activation may be elevated during the fasting state, and may therefore have 
already been near maximal during the experiment.  We may have seen different results 
had we not required subjects to be fasted during the experimental session. 
Additionally, glycogen is known to affect AMPK activity both by 
phosphorylation and independent of phosphorylation (McBride et al., 2009).  Muscle 
glycogen content before and after resistance exercise in young versus old subjects has not 
been previously examined.  There was a significant difference observed in glycogen 
content between the old and young groups at the pre-exercise time point.  This is in line 
with previous data, which shows a decrease in resting muscle glycogen levels with age 
(Cartee, 1994).  Additionally, the results of the current study showed a significant post-
exercise decrease for both young and old groups.  This is also consistent with published 
literature, as Tesch et al. showed a significant decrease in muscle glycogen content 
following resistive leg exercise in young subjects (Tesch et al., 1986). 
In this study, glycogen dropped to a greater degree in young than in old subjects 
after exercise and was statistically equal at every time point thereafter. This difference in 
glycogen loss may be a result of the different skeletal muscle fiber types found in young 
and old adults.  Previous research shows that age-related muscle loss occurs in the fast-
twitch muscle fibers as opposed to slow-twitch fibers (Welle, 2002).  As a result, older 
individuals have lower percentage fast-twitch fibers than young individuals [as reviewed 
(Andersen, 2003)].  Fast-twitch muscle fibers store and utilize more glycogen, which may 
be linked to the sharper decline in glycogen content from pre-exercise to immediately 
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post-exercise in the young subjects.  In addition, the similar glycogen content seen in the 
current study after exercise may have had a significant effect on ACC phosphorylation 
(i.e. AMPK activity) to produce a similar ACC phosphorylation in young and old 
subjects.  Indeed, there was a significant, or near significant, negative correlation between 
glycogen content and ACC phosphorylation status before, immediately post-, and one-
hour post-resistance exercise (Figures 4.12, 4.13, and 4.14). 
ACC phosphorylation (or AMPK activity) may have been impacted in the current 
study by the diet of the participants.  The older subjects in this study consumed total 
calories that were approximately 24% higher than the young subjects, which is not 
consistent with past research.  A study by Wurtman et al. (Wurtman et al., 1988) found 
that elderly individuals generally consume fewer total calories than their young 
counterparts.  The similarity between young and old subjects in the present study may 
have been a result of the low total calories consumed by the young subjects.  The young 
subjects averaged approximately 1,600 kcal per day, which is lower than would be 
expected in the young, healthy population (Wurtman et al., 1988).  Overall, the variance 
in diet from the expected norms may have partially caused the lack of difference 
observed in ACC phosphorylation (AMPK activity) in this study. 
FOXO3A phosphorylation (Ser 318/321) showed no significant difference in 
response to resistance exercise or between young and old groups across time points in the 
current study.  However, there was a non-significant (p = 0.17) pattern for the young 
group to have a higher FOXO3A phosphorylation response to exercise than the old 
group.  Additionally, in contrast to the negative correlation between glycogen content and 
phospho/total-ACC, phospho-FOXO3A showed a significant, or near significant, positive 
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correlation with muscle glycogen content over two post-resistance exercise time points.  
As previously mentioned, Akt phosphorylates FOXO3A, which sequester FOXO3A in 
the cytosol, block nuclear translocation, and ultimately blocks FOXO3A transcriptional 
activity.  However, AMPK activity inhibits this phosphorylation of FOXO3A by Akt, 
allowing FOXO3A to translocate into the nucleus of the cell.  Glycogen, on the other 
hand, blocks AMPK activity, allowing FOXO3A to be phosphorylated by Akt [as 
reviewed (Murton, Constantin & Greenhaff, 2008)].  Therefore, phospho/total ACC, 
reflecting AMPK activity, would be negatively correlated with muscle glycogen content, 
while phospho-FOXO3A would be positively correlated with glycogen content. 
A high positive relationship of phospho-FOXO3A with glycogen content was 
observed in the current study; thus, it was decided to separate the groups into high versus 
low glycogen content regardless of age.  A significant effect was observed when the 
groups were split in this fashion.  The high glycogen group showed an increase in 
FOXO3A phosphorylation, while the low glycogen group showed no change or a slight 
decrease in FOXO3A phosphorylation in response to resistance exercise.  The high and 
low glycogen groups were split based on pre-exercise (baseline) glycogen content. These 
results may provide practical implications.  Increasing glycogen content through diet may 
suppress the protein degradation pathway following resistance exercise.  Therefore, these 
results support altering nutritional intake to increase glycogen as a way to potentially 
decrease protein degradation regardless of age. 
A study performed by Nakashima and Yakabe (Nakashima and Yakabe, 2007) 
showed that AMPK activation stimulates FOXO3A.  However, this study looked at the 
effect of AMPK on FOXO3A mRNA and total protein, while the current study looked at 
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FOXO3A phosphorylation.    FOXO3A phosphorylation is a more acute, and therefore 
quicker, response, than creating a new protein.  FOXO3A phosphorylation is activated by 
Akt at Ser318/321.  This particular site was shown in a study by Tong et al. (Tong et al., 
2007) to cause FOXO3A to be phosphorylated in the cytoplasm and excluded from the 
nucleus of the cell.  This sequestering of FOXO3A by Akt decreases the effects of the 
protein degradation pathway. 
A strong association was not observed in the current study between phospho-
FOXO3A (Ser318/321) and AMPK activity (as measured by the phospho (Ser79)/total ACC 
ratio).  This argues against our hypothesis that a lower FOXO3A phosphorylation 
response would be related to higher AMPK activation, and suggests that a factor other 
than AMPK may more strongly mediate protein degradation pathway(s) following 
resistance exercise.  Based on previous research, this factor may be Akt.  Creer et al. 
(Creer et al., 2005) observed a higher phospho-Akt response to resistance exercise in a 
high vs. a low glycogen state.  This would have theoretically resulted in a higher 
FOXO3A (Ser318/321) phosphorylation, which was not measured in that study but is a 
finding of the current study under conditions of high pre-exercise muscle glycogen 
content.  Thus, with respect to the current study, we postulate that there was a higher Akt 
phosphorylation in response to resistance exercise under the high muscle glycogen 
condition, which may explain why the higher FOXO3A (Ser318/321) phosphorylation in 
that condition was not strongly related to lower AMPK activation.  In the same accord, 
our observed trend (albeit a weak one; p=0.17), of a higher FOXO3A (Ser318/321) 
phosphorylation response in younger vs. older subjects agrees with the results of 
Drummond et al., (Drummond, Dreyer et al., 2008), who found that the phospho-Akt 
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response to resistance exercise is diminished with increased age when compared to young 
subjects.  The potential link between glycogen content, Akt, and FOXO3A in response to 
resistance exercise, as well as how age may affect these responses, is a topic for future 
endeavors. 
There was a significant main effect seen in MuRF1 in the current study between 
young and old groups at 2-hours post-resistance exercise.  We measured total MuRF1 as 
an additional measure of protein degradation pathway activation in old versus young 
individuals; however, we did not expect to observe a response.  Nakashima and Yakabe 
(Nakashima and Yakabe, 2007) found that AMPK stimulates MuRF1 mRNA in skeletal 
muscle.  This study was performed on C2C12 myotubes.  Additionally, the time points in 
their study were different than the current study (6 hours and 24 hours as opposed to 
immediately post-exercise, 1-hour post- and 2-hours post-exercise).  Based on the 
findings of the current study and previous literature, it is reasonable to believe that the 
stimulation of MuRF1 by AMPK takes time; thus, the reason we found a significant main 
effect at 2 hours post-exercise is unclear. 
The current study provides instance for a number of future research endeavors.  
There were no significant differences between age groups shown in ACC, FOXO3A 
phosphorylation, and total MuRF1.  However, although no significant differences were 
observed between age groups, a high association was found between phospho/total ACC 
and phospho-FOXO3A with muscle glycogen content.  Studying nutritional differences 
on AMPK and the other markers of protein degradation would be beneficial, since 
previous literature shows AMPK phosphorylation differences between age groups 
following essential amino acid ingestion and carbohydrate supplement (Drummond, 
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Dreyer et al., 2008).  Additionally, it may prove beneficial to separate the muscle sample 
by fiber type (fast-twitch versus slow-twitch) to analyze protein degradation changes on 
the individual fiber types within old and young subjects. 
In summary, this investigation examined the FOXO3A Ser318/321 phosphorylation 
response to resistance exercise and its relation to muscle glycogen content and AMPK 
activation in young versus old subjects.  AMPK phosphorylation was increased in old, 
but not young, men and women, immediately following resistance exercise.  In addition, 
glycogen content was significantly lower in old subjects compared to young prior to the 
resistance exercise.  In both young and old groups, glycogen content decreased and 
remained decreased immediately post-exercise, as well as 1- and 2-hours post-exercise.  
Relationships were observed between glycogen content and both phospho/total ACC ratio 
and FOXO3A phosphorylation.  Higher glycogen content across all subjects was 
associated with a lower phospho/total ACC ratio (indicative of AMPK activity) and 
higher phospho-FOXO3A content.  Moreover, higher glycogen content prior to exercise 
was associated with significantly higher FOXO3A phosphorylation before, and in 
response to, resistance exercise, as well as a greater phospho-FOXO3A percent change 
from baseline with exercise.  These data indicate a strong association between glycogen 
content, AMPK activity, and FOXO3A signaling regardless of age.  However, a 
relationship between FOXO3A phosphorylation and AMPK activity was not observed, 
suggesting that another factor may play a role in activating the protein degradation 
pathway following resistance exercise in older individuals. 
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Practical Application 
Future research is needed to determine whether older adults with higher 
progression of sarcopenia show different results in the relationship between glycogen 
content and AMPK phosphorylation, ACC, and other markers of protein degradation.  It 
may be pertinent to suggest to young and old individuals alike to keep glycogen content 
high as a method to minimize activation of the protein degradation pathway in response 
to resistance exercise. 
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APPENDIX B: INFORMED CONSENT DOCUMENT 
 
Principal Investigator:  Scott E. Gordon, Ph.D. 
Institution:  Human Performance Laboratory 
Address:  363 Ward Sports Medicine Building 
Telephone #:  (252) 737-2879 
 
This consent form may contain words that I do not understand.  I should ask the study doctor or the 
study coordinator to explain any words or information in this consent form that I do not understand. 
 
INTRODUCTION 
 
I have been asked to participate in a research study being conducted by Scott E. Gordon, Ph.D. and his 
associates.  This research is designed to determine the response of several molecules in muscle after one 
resistance exercise (strength training) session, and if this response changes with age.  All of these 
molecules and cells are involved with muscle hypertrophy (growth). 
 
We will study 10 younger (18-45 years) and 20 older inactive adults (46-85 years), at rest 
and during and after a resistance exercise session for the legs.  Inactive is defined as not 
having participated in any regular form of exercise for the past six months (less than 30 
minutes per day, one day per week).  Studies will take place in the Human Performance 
Laboratory and Brody School of Medicine at East Carolina University. 
 
PLAN AND PROCEDURES 
 
Prior to any testing, I will report to the Human Performance Laboratory Fitness, 
Instruction, Testing, and Training (FITT) Building to first be allowed to read and sign 
this Informed Consent for research as then fill out a medical history questionnaire and 3-
day food record. I will be allowed to complete this process on the day of my first visit. 
On this day, I will then undergo determination of my height and body weight, and percent 
body fat.  I will also undergo strength testing and familiarization with the resistance 
exercise test.  One to two weeks later, I will report to the East Carolina Heart Institute 
Room 2379 in a fasted state for the resistance exercise testing session, four blood samples 
from a forearm vein, and 4 biopsies of the thigh muscles. 
 
The following section is an outline of the experimental visits and the procedures to 
be accomplished on each visit.  Note that more detailed descriptions of each 
procedure immediately follow this section.  There will be 2 visits for a total of 
approximately 5 hours of total participation time spread over approximately 2 
weeks: 
 
First Visit (Human Performance Lab FITT Building) (1.5 hours): 
1.) Thorough interview in person for informed consent, health history questionnaire, 
and 3-day food record. 
2.) Determination of height, weight, and skinfold thickness (fat pinch) for percent 
body fat. 
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3.) Determination of the maximum weight I can lift 10 times (10 repetition 
maximum, also called a 10 RM) for the seated leg extension exercise. 
4.) Counseling on food choices for those individuals undergoing the high 
carbohydrate diet, and instructions for keeping dietary logs. 
 
Second Visit (East Carolina Heart Institute Room 2379) (7-14 days after initial visit) (3.5 
hours): 
1.) I will report to the East Carolina Heart Institute Room 2379, in the morning after 
an overnight fast (not having eaten after midnight the night before). 
2.) Four small blood samples will be obtained during this visit from a forearm vein 
(before, and after exercise). 
3.) Four thigh muscle biopsies (tissue samples) will be performed during this session, 
two on each leg. 
4.) A resistance exercise (strength training leg extension) bout of approximately 15 
minutes focused on the thigh muscle group will be performed. The bout will 
consist of 6 sets of leg extension exercise.  
 
Detailed Description of the Procedures to be Used During this Study: 
• Body composition screening.  My height and weight will be measured on my first 
visit.  My body fat will be estimated by measuring skinfold thicknesses (fat pinch) 
with a skinfold caliper at four sites:  biceps, triceps, back, and waist.  I may feel a 
slight pinch or squeeze from the caliper at the skinfold sites, but no known risks 
are associated with this procedure. 
• Strength testing.  An exercise test to determine my strength levels and familiarize 
me with the resistance exercise protocol will be performed during my first visit 
(after the informed consent).  As part of my familiarization and subject 
characterization, I will be assessed for maximal strength by 10-repetition 
maximum (10-RM) testing.  This will entail determining the maximum amount of 
weight that I can lift in ten repetitions for the leg extension exercise.  This 
procedure will consist of me initially lifting lighter weights and progressing to the 
heaviest weight that I can lift.  An adequate amount of rest will be provided 
between repetition attempts.  All exercises will be performed on Cybex weight 
machines.  This session will also serve as a familiarization session to make me 
comfortable with the resistance exercise to be performed during the experimental 
session.  I will be examined for proper exercise technique during this session and 
instructions or modifications will be provided if necessary.  During this session, 
my tolerance for the heavy resistance exercise protocol will also be assessed. 
• High Carbohydrate Diet.  If I am one of the older subjects that is randomly 
selected to do the high carbohydrate diet, I will be instructed to eat a diet high in 
carbohydrates for the 3 days prior to my second visit to the laboratory.  I will be 
counseled on food choices and given food guidelines to assist with dietary choices 
during the initial visit.  The goal is for me to eat approximately 65-70% of my 
total calories from carbohydrates while attempting to decrease my calories from 
fat accordingly (protein intake will remain unaltered).  Some examples of high 
CHO food choices that are low fat but not low in protein are most vegetables, 
very lean meats, skim (non-fat) milk, etc.  Dr. Kimberly B. Heidal, PhD, MHS, 
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RD, LDN, from the ECU Dept. of Nutrition is a team member for this study and 
has provided guidelines and dietary instructions to help accomplish this goal.  
There is no anticipated risk to me while I undergo this level of carbohydrate 
consumption for 3 days.   
• Leg resistance exercise workout.  During my second visit to the laboratory, I will 
perform a 15-minute resistance exercise bout focused on the quadriceps (thigh) 
muscle group.  The bout will consist of 6 sets of leg extension exercise.  The first 
3 sets will be warm-up sets performed at 50% (8 repetitions), 70% (6 repetitions), 
and 90% (4 repetitions) of my previously determined 10-RM weight. The fourth 
through sixth sets will be performed at 100% of the 10 RM weight and will be 
performed until I am no longer able to perform them on my own (approximately 
10 repetitions).  I will rest for 90 seconds between all sets 
• Fasting blood draws.  I will not have anything to eat 12 hours prior to my second 
visit to the lab so that blood can be drawn from my forearm vein by a needle. 
During the second visit to the lab, blood will be drawn before, and after the 
resistance exercise workout described above.  Four total blood samples of 5 
milliliters each will be obtained during this study.  The total amount of blood 
obtained will be 20 milliliters, which is approximately 1/25 of a pint. 
• Muscle Biopsies.  I will undergo four muscle biopsies (tissue samples) to 
determine the levels of several molecules in muscle after one resistance exercise 
(strength training) bout.  These biopsies will be obtained immediately before, 
immediately after, and 1 and 2 hours after the resistance exercise bout in visit # 2.  
For this procedure, I will have a small amount of anesthesia (3 cc of 1% 
Lidocaine) injected in a ½ inch area under the skin of my thigh.  A small (1/4 
inch) incision will then be made through the skin, fat and fibrous tissue that lies 
over the muscle.  A biopsy needle (about ½ the width of a pencil) will then be 
inserted ½ to 1 inch into the muscle.  A small piece of muscle (½ the size of an 
eraser on the end of a pencil) will then be clipped out with the biopsy needle.  
The needle will be withdrawn and the muscle sample immediately preserved by 
freezing.  Dr. Robert Hickner, Ph.D. or Dr. Timothy Gavin, Ph.D. will perform 
the muscle biopsies.  These investigators have performed a total of over 500 
muscle biopsies. 
 
POTENTIAL RISKS AND DISCOMFORTS  
 
There are certain risks and discomforts that may be associated with this research, 
including those listed below. 
• The general performance of muscular exercise and physical effort can entail the 
potential hazards of injury from overexertion and/or accident.  The possibility of 
cardiopulmonary (heart and lung) overexertion is slight.  It will be minimized by 
screening, selection, and monitoring procedures which are designed to anticipate 
and exclude the rare individual for whom exercise might be harmful.  It is 
questionable whether it is possible to overexert the heart by voluntary physical 
effort unless there is some underlying disease.  Nevertheless, there are a number 
of disorders, some of which can readily escape clinical detection, where strenuous 
exercise may be potentially hazardous or may cause disability.  Some of these, 
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such as aneurysms (blood vessel ruptures) in the brain, solitary pulmonary cysts 
(small sacs of fluid in the lung), or alveolar blebs (small lung lesions), are rare 
and not readily diagnosed in the absence of symptoms.  For these disorders, a 
history of tolerance to prior physical effort must suffice.  For other, more common 
conditions such as ischemic heart disease (low blood and oxygen flow to the 
heart), several risk factors can be identified through the preliminary medical 
history and physician screening process. 
• The risks specifically associated with resistance exercise are very low, and this 
study will be planned to avoid injury to the musculoskeletal (muscle and bone) 
system.  Possible risks include the possibility of strains or pulls of the involved 
muscles, delayed muscle soreness 24 to 48 hours after exercise, muscle spasms 
(cramping), and, in extremely rare instances, muscle tears.  Such risks are very 
low.  Dizziness and fainting may also occur infrequently.  I understand that every 
effort will be made by the researchers to make this investigation safe for my 
participation through proper instruction of the techniques and proper warm-up 
prior to exercise and testing.  Furthermore, risks will be reduced by close 
supervision by experienced personnel to ensure that I utilize proper form. 
• The total amount of blood drawn (1/25 of a pint) is negligible. There is an 
extremely small risk of local hematoma (bruising) or infection associated with 
insertion of venipuncture needles.  In obtaining blood samples from a vein with a 
needle, the risks to me are of local discomfort, syncope (faintness), and 
hematomas (bruising).  Thrombosis (blood clot in the vein), embolism (a blood 
clot that has come loose and may lodge itself in an artery), and infections are 
potential risks but are of very rare occurrence.  Risks will be reduced or 
eliminated by having investigators who are trained and proficient in phlebotomy 
(puncturing veins with needles) use aseptic techniques.  Furthermore, I will be in 
a seated position while blood is being obtained.  All blood samples will be drawn 
in the laboratory under aseptic conditions with biohazard protection for the 
investigators and myself. 
• Robert Hickner, Ph.D. or Dr. Timothy Gavin, Ph.D. will perform all biopsies, and 
Dr. Walter Pofahl, M.D. will provide medical coverage for biopsies performed in 
this investigation.  There is a small risk of hematoma (bruising) or infection 
around the biopsy site, as well as muscle cramping, mild muscle tenderness and 
occasional bruising.  The risk will be minimized by using sterile procedures and 
applying pressure to the biopsy site for 10 minutes, or until bleeding has stopped 
if longer than 10 minutes.  A steri-strip (bandage) will be applied over the incision 
and will remain in place for at least 4 days to close the incision during healing.  A 
pressure wrap will be placed around the biopsied thigh and will remain in place 
for 8 hours following the biopsy.  There is an extremely remote risk of allergic 
reaction to the Lidocaine anesthesia.  This risk will be minimized by using 
subject’s who have had prior exposure to Lidocaine or Novocaine anesthesia.  
This precaution should eliminate this risk.   
• The procedures and circumstances encompassed by this protocol provide for a 
high degree of safety.  Every attempt will be made by the investigators to 
minimize any risks of this study to me.  This includes familiarization, technique 
instruction and practice, supervision by experienced personnel, screening, and 
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individualized testing and monitoring.  The investigators will employ a close 
interaction with the physician in their clinical unit during this study.  My safety 
will be enhanced in this study with individualized supervision during all 
laboratory visits.  I will be asked to immediately alert a member of the research 
team if I have any injury or health problem.  These factors should dramatically 
contribute to a reduction, if not an elimination, of any potential risks associated 
with this study. 
• There is the potential risk that the results, especially if unfavorable or difficult to 
understand, may lead to my anxiety.  However, I understand that the investigators 
are available to answer any of my questions or concerns regarding such matters, 
even after termination of the study. 
• To my knowledge, I am not allergic to “caine-type” anesthetics. For example, 
I have not had an allergic reaction to an injection at the dentist’s office. To 
my knowledge, I do not possess any condition which would result in excessive 
bleeding and I do not have known heart disease, i.e., had a heart attack. 
• I am aware that there are unforeseen risks involved with this and all research 
studies. 
 
POTENTIAL BENEFITS 
 
There are potential benefits to society.  The results of this study will help to determine the response of 
several muscle growth-related molecules and cell types in muscle after one resistance exercise (strength 
training) session, and if this response changes with age.  The benefits of this study far outweigh the risks. 
There are potential benefits to subjects.  I will gain information about my blood sugar (glucose) and insulin levels, which may be 
indicators of health status due to the importance of blood glucose regulation.  These blood glucose and insulin values will be available 
to me at any time if I request them.  Furthermore, if my blood glucose and insulin values fall outside of the normal clinical range, I 
will be contacted by the investigators and advised to consult my personal physician.  I will obtain information about my percent body 
fat and body mass index (BMI, or weight/height squared), which is also an important indicator of risk for metabolic diseases such as 
diabetes or heart disease.  I will also gain information on my muscle fiber type (slow-twitch or fast-twitch), which is important 
component of athletic ability characteristics. 
 
I will be paid a total of $200.00 compensation upon completion of the entire study. 
 
SUBJECT PRIVACY AND CONFIDENTIALITY OF 
RECORDS 
 
Only the investigators associated with this study will have access to the data obtained.  
The identity of the subjects will be protected by numeric coding.  The data will be stored 
in the office of the Principal Investigator, or in a locked storage room. No identifying 
information will be released. 
 
TERMINATION OF PARTICIPATION 
 
My participation in this research study may be terminated without my consent if the 
investigators believe that these procedures will pose unnecessary risk to myself.  I may 
also be terminated from participation if I do not adhere to the study protocol. 
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COST AND COMPENSATION 
 
I will be paid $50.00 for my time and inconvenience for each muscle biopsy for a 
maximum of $200 for completion of the entire study. There are no costs to me for 
participation in this study. 
 
The policy of East Carolina University does not provide for 
compensation or medical treatment for subjects because of 
physical or other injury resulting from this research activity.  
However, every effort will be made to make the facilities of the 
School of Medicine available for treatment in the event of such 
physical injury. 
 
VOLUNTARY PARTICIPATION 
 
I understand that my participation in this study is voluntary.  Refusal to participate will involve no penalty or loss of benefits to which 
I am otherwise entitled.  Furthermore, I may stop participating at any time I choose without penalty, loss of benefits, or without 
jeopardizing my continuing medical care at this institution. 
 
RESEARCH PARTICIPANT AUTHORIZATION TO USE AND DISCLOSE 
PROTECTED HEALTH INFORMATION 
 
The purpose of the information to be gathered for this research study is to better 
understand the response of several molecules in muscle after one resistance exercise 
(strength training) session, and if this response changes with age.  The individuals who 
will use or disclose my identifiable health information for research purposes include Dr. 
Scott Gordon, Dr. Timothy Gavin, Dr. Robert Hickner, Dr. Walter Pofahl, and Mr. 
Bradley Harper.  Individuals who will receive my identifiable health information for 
research purposes also include Dr. Scott Gordon, Dr. Timothy Gavin, Dr. Robert 
Hickner, Dr. Walter Pofahl, and Mr. Bradley Harper.  The type of information accessed 
for this research study includes 1) general medical history (including family health 
history, medications, nutrition, physical activity levels and body weight history), 2) body 
composition information, blood levels of insulin, glucose, and other compounds related to 
muscle hypertrophy and metabolism, and 3) muscle fiber type percentage as well as 
growth-related molecules in my thigh muscle.  The information will be used and 
disclosed in such a way as to protect my identity as much as possible; however, 
confidentiality cannot be absolutely guaranteed.  Someone receiving information 
collected under this Authorization could potentially re-disclose it, and therefore it would 
no longer be protected under the HIPAA privacy rules (federal rules that govern the use 
and disclosure of my health information).  There is not an expiration date for this 
Authorization. 
 
I may not participate in this study if I do not sign this Authorization form.  I may revoke 
(withdraw) this Authorization by submitting a request in writing to Dr. Scott Gordon.  
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However, the research team will be able to use any and all of the information collected 
prior to my request to withdraw my Authorization.   
 
To authorize the use and disclosure of my health information for this study in the way 
that has been described in this form, I must sign below and date when I signed this form.  
A signed copy of this Authorization will be given to me for my records. 
 
________________________________________________________________________ 
Participant’s Name (print)                              Signature                                        Date  
 
________________________________________________________________________ 
Authorized Representative Name (print)-----Relationship        Signature             Date  
 
________________________________________________________________________ 
Person Obtaining Authorization                     Signature                                         Date  
 
If I have questions related to the sharing of information, I am advised to call Scott 
Gordon at 252-737-2879.  I may also telephone the University and Medical Center 
Institutional Review Board at 252-744-2914.  In addition, if I have concerns about 
confidentiality and privacy rights, I may phone the Privacy Officer at Pitt County 
Memorial Hospital at 252-847-6545 or at East Carolina University at 252-744-2030. 
 
PERSONS TO CONTACT WITH QUESTIONS 
 
The investigators will be available to answer any questions concerning this research, now 
or in the future.  I may contact the primary investigators Scott E. Gordon, Ph.D. at 252-
737-2879 (weekdays) or 252-321-7655 (nights and weekends).  Also, if questions arise 
about my rights as a research subject, I may contact the Chairman of the University and 
Medical Center Institutional Review Board at phone number 252-744-2914 (weekdays).  
 
CONSENT TO PARTICIPATE 
 
I certify that I have read all of the above, asked questions and received answers 
concerning areas I did not understand, and have received satisfactory answers to these 
questions. I willingly give my consent for participation in this research study.  (A copy of 
this consent form will be given to the person signing as the subject or as the subject’s 
authorized representative.) 
 
_____________________________________________________________ 
Participant’s Name (Print) 
 
_____________________________________________________________ 
Signature of Participant    Date  Time 
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WITNESS:  I confirm that the contents of this consent document were orally presented, 
the participant or guardian indicates all questions have been answered to his or her 
satisfaction, and the participant or guardian has signed the document.  
 
 
_____________________________________________________________ 
Witness’s Name (Print) 
 
_____________________________________________________________ 
Signature of Witness      Date   
 
 
PERSON ADMINISTERING CONSENT:  I have conducted the consent process and 
orally reviewed the contents of the consent document. I believe the participant 
understands the research. 
 
_____________________________________________________________ 
Person Obtaining Consent (Print) 
 
_____________________________________________________________ 
Signature of Person Obtaining Consent        Date 
 
 
 
_____________________________________________________________ 
Principal Investigator’s Name (Print) 
 
_____________________________________________________________ 
Signature of Principal Investigator          Date 
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FUTURE TESTING OF BLOOD/MUSCLE SAMPLES 
 
Upon termination of this study, the blood and muscle samples collected for this study 
will be stored for up to 7 years to research scientific questions specifically related to age-
related changes in molecules regulating muscle mass in response to resistance exercise.  I 
understand that I have the right to decline consent for this storage beyond termination of 
the present study, and that this declination of consent would not exclude me from 
participation in the present study.  I will continue to be the owner of the samples and 
retain the right to have the sample material destroyed at any time during this study by 
contacting the study principal investigator Scott Gordon, Ph.D. at 252-737-2879.  During 
this study, the samples will be stored with number identifiers only; however, the number 
identifier will be linked to a specific name and will be kept on file in the possession of 
the principal investigator.  The linked file will be stored password protected on the 
Principal Investigator’s computer with CD backup.  No other individuals will have 
access to these identifying materials unless the principal investigator is required by law 
to provide such identifying information.  Data will not be publicly available and 
participants will not be identified or linked to the samples in publication.  If a 
commercial product is developed from this research project, I will not profit financially 
from such a product.  Furthermore, there are no plans for me to profit financially from 
such a product.   
 
 
CONSENT TO PARTICIPATE IN FUTURE 
TESTING OF BLOOD/MUSCLE SAMPLES  
 
I certify that I have read all of the above, asked questions and received answers 
concerning areas I did not understand, and have received satisfactory answers to these 
questions.  I willingly give my consent for participation in this research study.  (A copy 
of this consent form will be given to the person signing as the subject or as the subject’s 
authorized representative.) 
 
_____________________________________________________________ 
Participant’s Name (Print) 
 
_____________________________________________________________ 
Signature of Participant    Date  Time 
 
WITNESS:  I confirm that the contents of this consent document were orally presented, 
the participant or guardian indicates all questions have been answered to his or her 
satisfaction, and the participant or guardian has signed the document.  
 
 
_____________________________________________________________ 
Witness’s Name (Print) 
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_____________________________________________________________ 
Signature of Witness      Date   
 
 
PERSON ADMINISTERING CONSENT:  I have conducted the consent process and 
orally reviewed the contents of the consent document. I believe the participant 
understands the research. 
 
_____________________________________________________________ 
Person Obtaining Consent (Print) 
 
_____________________________________________________________ 
Signature of Person Obtaining Consent        Date 
 
 
 
_____________________________________________________________ 
Principal Investigator’s Name (Print) 
 
_____________________________________________________________ 
Signature of Principal Investigator          Date 
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APPENDIX C:  PERSONAL HISTORY FORM 
 
PERSONAL HISTORY FORM                                                           (version 2-17-09) 
 
Technician _______________________    Contract ________________  ID _________ 
 
   PLEASE PRINT AND FILL OUT  COMPLETELY  
 
1. Name: ______________________________  Date: ___________________ 
 Phone#: (home) ____________________ (work) ________________________ 
 Address: __________________________________________________________ 
 City: _______________________ State ___________  Zip ______________ 
 e-mail address (if available):___________________________________________ 
2. Employer: ________________________________________________________ 
 Occupation: _______________________________________________________ 
 
3. Date of Birth: ________________ Sex: _______   Age: _______ Race:  _______ 
 
4.  General Medical History                    Circle one  
Any medical  complaints presently?    (if yes, explain) ....                                     yes    no 
____________________________________________________________ 
____________________________________________________________ 
____________________________________________________________ 
 
Any major illnesses in the past?  (if yes, explain) ..... (date) ______         yes   no 
____________________________________________________________ 
____________________________________________________________ 
____________________________________________________________ 
 
Any hospitalization or surgery?  (if yes, explain)  ......    (date)  _________          yes    no 
____________________________________________________________ 
____________________________________________________________ 
____________________________________________________________ 
 
Have you ever had an EKG (electrocardiogram) ? ......    (date)  _________         yes    no 
 
 
Are you diabetic?  ....If yes, at what age did you develop diabetes: _________    yes    no 
 
Are you currently taking any medications? .............................          yes    no 
 
Medication  Dosage Reason  Times taken per day 
______________________________________________________________________ 
______________________________________________________________________ 
 
5.  Family History 
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  Age if    Age of   Cause of 
  alive    death   death 
Father  ______   ________ ____________________ 
Mother ______   ________ ____________________ 
 
 
 
Do you have a family history of: (Blood relatives only: give age of occurrence if 
applicable)        Relationship  
 Age of 
          
 occurrence 
--High blood pressure ...... yes    no   ______________________________ 
--Heart attack.....................yes    no   ______________________________ 
--By-pass surgery...............yes    no   ______________________________ 
--Stroke..............................yes    no   ______________________________ 
--Diabetes...........................yes    no               ______________________________ 
--Gout.................................yes    no   ______________________________ 
--Obesity.............................yes    no              ______________________________ 
 
6.  Tobacco History  (check one) 
_____   None       Cigarette history 
_____   Quit months/years ago    _____   1-10 daily 
_____   Cigarette      _____    11-20 “ 
_____   Snuff       _____    21-30 “ 
_____   Chewing tobacco      _____    31-40   “ 
_____   Pipe       _____    more than 40 
Total years of tobacco use? _______     
 
Snuff history       Chewing history  
______   < 0.5 cans daily     _____   < 0.5 pouches daily 
______   0.5-2.5 cans  “     _____   0.5-2.5 pouches  “ 
______   > 2.5 cans     “      _____   > 2.5 pouches     “ 
 
7. Weight History  
What do you consider a good weight for you? ________ Weight at age 21? _________ 
Weight since age 21? ________    Weight one year ago? ______ 
Weight now? ________ 
 
8. Cardio-Respiratory History 
 
Any heart disease now?..........................................................................................    yes  no 
 
Any heart disease in the past?................................................................................  yes  no 
 
Heart murmur?........................................................................................................ yes  no 
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Occasional chest pains?........................................................................................    yes  no 
 
Chest pains on exertion?.........................................................................................  yes  no 
 
Fainting?.................................................................................................................  yes  no 
 
Daily coughing?.....................................................................................................  yes  no 
 
Cough that produces sputum?............................................................................... . yes  no 
 
High blood pressure?.............................................................................................  yes  no 
 
Shortness of breath -- 
 at rest.......................................................................................................    yes  no 
 lying down..............................................................................................    yes  no 
 sleeping at night.....................................................................................    yes  no 
 after 2 flights of stairs...........................................................................     yes  no 
 
9.  Muscular  History 
 
Any muscle injuries or illnesses now?................................................................    yes  no 
 
Any muscle injuries in the past?.........................................................................    yes  no 
 
Muscle pain at rest?............................................................................................    yes  no 
 
Muscle pain on exertion?...................................................................................    yes  no 
 
10.  Bone-Joint History 
 
Any bone or joint (including spinal) injuries or illnesses now?........................    yes  no 
 
Any bone or joint (including spinal) injuries or illnesses in the past?..............    yes  no 
 
Ever had painful joints?....................................................................................   yes  no 
 
Ever had swollen joints?..................................................................................    yes  no 
 
Flat feet?...........................................................................................................   yes  no 
 
11.  Menstrual History (Women only) 
 
Are you post-menopausal (e.g., not had menstrual flow for at least one year)? ... yes  no 
 
Have you had a hysterectomy? .............................................................................    yes  no 
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If you have had a hysterectomy, were the ovaries removed? ………………......    yes  no 
 
If pre-menopausal:  On what date did your last period start (beginning of flow)? 
____________ 
 Are your periods regular? .....................................................    yes  no 
Approximately how many days apart are your periods?      
_____________ 
Are you on any hormonal supplements, such as a birth control pill or 
estrogen replacement therapy? .............................................................................    yes  no 
 If so, what? ________________________________ 
 
12.  Nutritional Survey 
How many times do you usually eat per day?                                                  
 ________ 
 
What time of day do you eat your largest meal?                                              
 ________ 
 
How many times per week do you usually eat...     
 ____ Hamburger ____ Sausage  ____ Bacon 
 ____ Beef  ____ Pork  ____ Cheese 
 ____ Shellfish (shrimp, oysters, scallops, clams, etc.) 
 ____ Fish  ____Poultry  ____ Fried Foods 
 ____ Breads  ____ Cereals  ____ Vegetables 
 ____ Eggs  ____ Desserts  ____ Ice Cream 
 ____ Other 
 
How many servings per week do you usually consume? 
____ Whole milk   ____ Coffee 
____ Low-fat milk (2% milk fat) ____ Tea 
____ Skim milk (non-fat)  ____ Soft drinks 
____ Buttermilk   ____ Other 
 
 
 
 
 
13.  Physical Activity Survey 
a.  Compared to a year ago, how much regular physical activity do you currently get?  
(Check One) 
 ____  much less  ____  somewhat less  ____  about the same 
 ____  somewhat more  ____  much more 
 
b.  For the last three months, have you been exercising on a regular basis?............  yes  no 
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c.  What type of exercise or physical activity do you currently do or have done regularly 
in the past?   
     (For example:  walking, swimming, weight lifting, gardening, etc.)  
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
 
d.  On the average, how many days per week do you exercise? _______ 
 
e.  How long do you exercise each time?  For how many minutes?  __________________ 
 
f.  How hard do you exercise on a scale from 1 to 5:  with 1 being easy and 5 being very 
hard? 
 ____ 1  ____ 2  ____ 3  ____ 4  ____ 5 
 
g.  Do you ever check your heart rate (pulse) to determine how hard you are exercising? 
 ____ yes ____ no 
 
h.  What aerobic activity or activities would you prefer in a regular exercise program for 
yourself? 
____ Walking and/or running  ____ Tennis   ____ Bicycling 
____ Racquetball   ____ Swimming  ____ Basketball 
____ Aerobic dance   ____ Stationary cycling ____ Soccer  
____ Stair climbing   ____ Rowing   ___________Other 
  
14.  Alcohol History 
Do you ever drink alcoholic beverages?    Yes ____  No ____  
If yes, what is your approximate intake of beverages per week?   
Beer _____ Wine _____ Mixed Drinks _____   
 
15.  Sleeping Habits 
Do you ever experience insomnia (trouble sleeping)? Yes ____ No ____ 
If yes, approximately how 
often?___________________________________________________ 
How many hours of sleep do you usually average per 
night?_____________________________ 
 
16.  Education 
Please indicate the highest level of education completed. 
____ Grade School  ____ Junior High  ____ High School  
____ College   ____ Graduate  ____ Postgraduate 
Please indicate degree earned (i.e. B.A., M.S., Ph.D.)_____________________________ 
  
 
17.  Motivation or reason for participating in the testing program? 
____ General health and fitness evaluation 
102 
 
____ Medical evaluation prior to starting and exercise program 
____ Baseline for weight loss 
____ Required by supervisors or employers 
____ Other ______________________________________________________ 
 
18.  Family Physician 
Name:  _________________________________________________________ 
Address:________________________________________________________ 
Phone:  _________________________ 
Should it be necessary, may we send a copy of your results to your physician? 
 
19.  Insurance  I, _____________________understand that this evaluation is not 
reimbursable under Medicare and the cost of the evaluation must be paid by me. 
 
Signature:  ________________________________ 
Date:  ___________________________________ 
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APPENDIX D:  DIETARY LOG FOR A TYPICAL DAY 
Date _________________    Subject ID # _____________ 
 
Dietary Log for a Typical Day 
 
Meal Time of 
day 
Serving 
Size 
Food Item Prepared by: 
   
 
 
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
 
Please list all other vitamins, minerals, and supplements that you normally take in a 
day: ___________________________________________________________________ 
_______________________________________________________________________ 
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APPENDIX E:  EXPERIMENTAL SESSION INSTRUCTIONS 
Age-related Changes in Skeletal Muscle Signaling after Acute Heavy 
Resistance Exercise 
 
Principal Investigator:  Scott E. Gordon, Ph.D. 
Telephone #:  (252) 737-2879 
Sub Investigators:  Hope Tharrington/Jen Macesich 
Telephone #:  (252) 883-2001/ (919) 606-2853 
 
EXPERIMENTAL SESSION INSTRUCTIONS 
 
Human Performance Laboratory 
 
 
 
For three full days prior to session (Start Date: ): 
 1. Do not drink alcohol. 
 2. If you consume caffeine, do so only in moderation. 
 3. Drink at least 64 oz. of water per day (i.e., eight 8-oz. glasses). 
  
On day of experimental session (Date: ): 
 1. Drink 16 oz. of water before reporting to the laboratory. 
 2. **Do not eat or drink anything but water for the 12 hours prior to reporting to the 
laboratory!! 
 3. **Do not exercise before the experimental session!! 
 4. Report to the East Carolina Heart Institute at _________________.   
 5. Wear exercise clothes, specifically shorts and athletic shoes, to the experimental session. 
 
For the duration of the experiments: 
 1. Do not engage in exercise. 
 2. Do not donate blood or plasma. 
 3. If you begin taking new medications, please notify Hope Tharrington/Jen Macesich. 
 
